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Abstract 
 Numerous studies suggest that modulation of the cholinergic system through the use of 
nicotinic agonists can improve motor function in humans or animals with motor disorders. 
Specifically, although there are no approved therapeutics for patients with ataxia, the nicotinic 
receptor agonist varenicline has demonstrated efficacy to improve coordination and gait in 
several groups of patients with different subtypes of ataxia. Importantly, the mechanism 
underlying the varenicline’s mechanism of action to improve motor function remains to be 
elucidated. Thus, the purpose of these experiments was to first quantify gait impairments in rats 
with olivocerebellar ataxia utilizing an objective treadmill-based system to investigate 
temporospatial aspects of animals’ gait. These results were used to calculate an index that 
characterizes deviations from ‘normal’ gait, as similarly employed in clinical studies. The 
translational validity of this method of gait assessment was investigated by comparing gait 
impairments between these animals and those reported for humans with ataxia. It was next 
investigated whether varenicline could attenuate any gait impairments and thus improve motor 
functioning in these animals, as suggested by clinical findings. Finally, varenicline’s mechanism 
of action was investigated by attempting to block its effects by pretreating animals with the 
nicotinic antagonist mecamylamine. Thus, these studies demonstrate the involvement of 
nicotinic acetylcholine receptors in the mechanism of varenicline’s effects to improve motor 
functioning. Moreover, these results provide translational methods by which the efficacy of 
other, more selective nicotinic agonists to improve motor functioning can be tested preclinically 
prior to their use in humans with ataxia.  
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Chapter One: 
Introduction 
 
Modulation of the cholinergic system for the treatment of neurodegenerative and motor 
disorders 
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1.1. Lack of therapies for patients with ataxia 
In conjunction with other motor areas in the brain, one of the main roles of the 
cerebellum is the regulation of balance and motor coordination during locomotion. Thus, one of 
the most characteristic signs of cerebellar damage is ataxia (Morton and Bastian, 2004), derived 
from Latin meaning “disorderly”. Ataxia can be acquired from chemical insults including chronic 
ethanol administration (Hansen and Pulst, 2013), or Δ9-tetrahydrocannabinol (Smith and Dar, 
2007), or following a stroke or trauma to the cerebellum. Furthermore, some subtypes of ataxia 
can be inherited, consisting of autosomal dominant (e.g. the spinocerebellar ataxias), autosomal 
recessive (e.g. Friedreich’s ataxia) (Schöls et al., 2004), X-linked (e.g. Fragile X-associated 
tremor ataxia syndrome), or the result of point mutations (Perlman, 2000).  
Unfortunately, there is no effective pharmacological treatment for ataxia, partly due to 
the heterogeneity of the ataxia population. As is the case with other progressive 
neurodegenerative disorders, treatment options are limited to managing symptoms of the 
disorder, reducing side effects as a consequence of medications, and maintaining patient 
quality-of-life. Physical therapy exercises limited to single joints consisting of nonfatiguing slow 
repetitive rhythmic movements may improve motor functioning in patients with ataxia (Bastian, 
1997); however, physical therapy alone will not cure the disorder and may not slow its 
progression, especially in patients with degenerative subtypes of ataxia that become 
progressively less mobile over time.  Numerous studies have been undertaken in an attempt to 
find therapeutics for patients with ataxia of varying subtypes, including: the antiviral and 
antiparkinsonian drug amantadine (Peterson et al., 1988; Botez et al., 1996); serotonergic 
compounds including L-5-hydroxytryptophan (Trouillas et al., 1988; 1995) and buspirone 
(Trouillas et al., 1997b); the carbonic anhydrase inhibitor acetazolamine (Jen et al., 1998; 
Lubbers et al., 1995); and the anti-epileptic drug carbamazepine (Sechi et al., 1989). 
Unfortunately, results of these studies have been mixed, with some studies demonstrating that 
these drugs could reduce the symptoms of ataxia and others suggesting no beneficial effect 
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(reviewed in Perlman, 2000). Furthermore, while these drugs may provide some benefit for 
treating specific symptoms of ataxia including tremor, vertigo, and nystagmus, their off-target 
effects can manifest numerous side effects that have hampered their use to treat patients with 
ataxia. 
However, it has been documented that modulation of the cholinergic system may be 
useful for treating motor dysfunction in patients with or animal models of motor disorders, 
including ataxia.  For example, preclinical evidence indicates that nicotine and other nicotinic 
agonists can reduce L-DOPA-induced dyskinesias in several animal models of Parkinson’s 
disease (Quik et al., 2014). Nicotine has also been shown to reduce the occurrence and severity 
of motor tics when given concurrently with haloperidol in patients with Tourette’s syndrome 
(Silver et al., 2001). Furthermore, it has been documented that patients with cerebellar and 
Friedreich’s ataxia have cholinergic deficiencies (Barbeau, 1978; Manyam et al., 1990; Hirano et 
al., 2008). Although several studies have demonstrated that treatment with the cholinesterase 
inhibitor physostigmine or the acetylcholine precursor choline may have some benefit for certain 
patients with ataxia, these treatments have not been effective in double-blind clinical trials 
(Lawrence et al., 1980; Wessel et al., 1997), perhaps due to the heterogeneity of the ataxia 
population. Recently, several clinical reports and one double-blind clinical trial have documented 
that varenicline (Chantix™), a neuronal nicotinic acetylcholine receptor (nAChR) agonist 
currently prescribed for smoking cessation, improved symptoms in patients with varying 
subtypes of ataxia (Zesiewicz and Sullivan, 2008; Zesiewicz et al., 2009a; Zesiewicz 2009b; 
Zesiewicz et al., 2012). The underlying mechanism mediating these improvements in motor 
function in these patients is as yet unknown; however, it is likely that it involves modulation of 
the cholinergic system through nicotinic receptor signaling. 
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1.2. Neuronal nicotinic acetylcholine receptors 
Neuronal nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated ion 
channels found throughout the central nervous system. Neuronal nAChRs can be comprised of 
heteromeric combinations of α (α2-10) and β (β2-4) subtypes (e.g. α4β2, α3β4) as well as 
homomeric conformations (e.g. α7 ) (Millar and Gotti, 2009). Neuronal nAChRs, especially those 
of the α7 subtype, are highly permeable to calcium (McGehee and Role, 1995), and can 
desensitize following chronic exposure to nicotine and nicotinic agonists. In the rat, nAChR 
expression is diffuse throughout the brain, with the α4β2 subtype being the most widely and 
abundantly expressed (Wada et al., 1989).  The expression of α7 receptors is more limited to the 
cerebrum, hypothalamus, hippocampus, and some brain stem nuclei (Séguéla et al., 1993). In 
addition to being expressed throughout the brain, other neuronal nicotinic receptor subtypes can 
be found in the autonomic ganglia (e.g. α3β4) (Wang et al., 2002). Conversely, non-neuronal 
nicotinic receptors are found within the neuromuscular junction and can be comprised of γ, ε, or 
δ subtypes in combination with the α1 and β1 subtype (Millar and Gotti, 2009).  
In response to binding of an agonist, neuronal nAChRs undergo a conformational 
change that opens the receptor pore to allow the passage of ions. Depending upon the 
concentration and duration of available agonists, the receptor can desensitize and become 
transiently inactive, or it can close, rendering the receptor functionally inactive. However, this 
description is overly simplistic, in that rather than always proceeding through a linear 
progression of these distinct conformations, nicotinic receptors can cycle through these states 
(Katz and Thesleff, 1957) as a result of the concentration and duration of agonist present 
(Changeux et al., 1984). Furthermore, evidence suggests that nicotinic receptors can exist in at 
least two distinct desensitized states in which receptors exhibit an intermediate and high-affinity 
for ligands (Feltz and Trautmann, 1982). Importantly, since nAChRs exist as numerous 
subtypes, they differ greatly in their pharmacological and physiological responses including 
cation permeability, rate of desensitization, and affinity for ligands. 
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Since many neuronal nAChRs are located presynaptically, it has been hypothesized that 
their primary role in the CNS is to modulate neurotransmitter release from neurons (Wonnacott, 
1997, Vizi and Lendvai, 1999, Salminen et al., 2004). Indeed, when activated, presynaptic 
nAChRs can facilitate the release of neurotransmitters including dopamine, norepinephrine, 
serotonin, acetylcholine, γ-aminobutyric acid (GABA), and glutamate (Shimohama, 2009). This 
can occur through nAChR activation from binding of a ligand, resulting in Ca2+ influx through the 
receptor, by the activation of additional voltage-gated Ca2+ channels as a result of the proximal 
influx of Ca2+ , resulting in a depolarization, or by increasing the amount of intracellular Ca2+  
through the recruitment of Ca2+  from intracellular stores (Mudo et al., 2007).  
Activation of nicotinic receptors by nicotine and the corresponding Ca2+ influx has been 
documented to induce several downstream second messenger cascades, including protein 
kinase C (PKC) (Fenster et al., 1999), phospholipase C (PLC) (Pandey, 1996), Ca2+-dependent 
CaM-kinase II (Damaj, 2000), and MAPK/Erk 1/2 activity (Cox et al., 1996). Also, activation of 
CaM-kinase II or MAPK cascades, as well as increases in intracellular Ca2+ or cAMP levels can 
lead to cAMP response element-binding protein (CREB) phosphorylation and activation (Chang 
and Berg, 2001), which has been implicated in the transcription of a number of genes involved 
in learning, memory, long-term potentiation (LTP), and synaptic plasticity (Sweatt, 2001; Barco 
and Marie, 2011). Since nAChR activation can affect gene regulation through the activation of 
Ca2+-mediated second messenger cascades, nicotinic receptors can also modulate synaptic 
plasticity and neuronal survival (Belluardo et al., 2000), and thus, activation of nicotinic 
receptors has been documented to have anti-apoptotic effects as a result of increased 
expression of various pro-survival factors (reviewed in Schaal and Chellappan, 2014). 
 
1.3. Neuroprotective effects of nicotine and other nicotinic agonists 
Nonselective activation of nicotinic receptors through the use of nicotine has been 
documented to have neuroprotective effects in diverse experimental situations. For example, 
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nicotine can protect against NMDA-mediated excitotoxicity (Kaneko et al., 1997; Semba et al., 
1996), and can protect dopaminergic neurons from degeneration when both 1-Methyl-4-phenyl-
1,2,3,6- tetrahydropyridine (MPTP) and methamphetamine are used to induce neurotoxicity and 
model Parkinson’s disease in animals (Janson et al., 1988; Maggio et al., 1998). Furthermore, 
aged mice lacking β2 nAChRs, which bind nicotine with high affinity, exhibit increased 
neurodegeneration and memory deficits (Zoli et al., 1999), and patients with Parkinson’s and 
Alzheimer’s disease similarly exhibit declines in high-affinity nAChR expression that may partly 
underlie the cognitive and motor deficits exhibited in these patients (Nordberg et al., 1992; Perry 
et al., 1995). Cholinesterase inhibitors (e.g. donepezil and rivastigmine) currently comprise first-
line therapies to alleviate cognitive impairments such as dementia in patients with Alzheimer’s 
and Parkinson’s disease (reviewed in: Pagano et al., 2015; Wang et al., 2015; Tan et al., 2014). 
However, off-target effects of these drugs can result in unwanted side effects, and thus, the 
efficacy of more selective nicotinic agonists to improve cognitive and motor impairments is  
being investigated as another viable treatment option (Potter et al., 1999; Quik et al., 2015). 
Specifically, the neuroprotective effects following nicotine administration appear to be 
selectively mediated through either the α4β2 or α7 subtype. For example, α4β2 activation appears 
to be neuroprotective in striatal and cortical neurons, as α4β2 knockout-mice do not exhibit 
similar neuroprotective effects following nicotine administration compared to wild-type animals 
(Ryan et al., 2001; Laudenbach et al., 2002) and α7 activation is neuroprotective in hippocampal 
neuron cultures, an effect that can be blocked by the α7-selective antagonists methyllycaconitine 
or α-bungarotoxin (Dajas-Bailador et al., 2000). These findings have led to the development of 
more selective nicotinic agonists at α4β2 (e.g. ABT-418; ABT-089) or α7 nAChRs (e.g. GTS-21; 
ABT-107) that have also been documented to be neuroprotective (Donnelly-Roberts, et al., 
1996; Sullivan et al., 1997; Nanri et al., 1997; Bordia et al., 2015).  Thus, since many patients 
with a movement disorder also exhibit some degree of neurodegeneration (e.g. Parkinson’s 
disease, Friedrich’s ataxia, Huntington’s disease, and multiple system atrophy) the use of 
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selective nicotinic agonists may improve motor function or slow the progression of the disorder, 
with fewer side effects.  
 
1.4. Use of nicotinic agonists for the treatment of motor disorders 
In addition to having neuroprotective effects, studies have also documented that the 
administration of nicotinic agonists can improve motor function in patients with motor disorders. 
As discussed in Section 1.1, the nicotinic agonist varenicline has shown some promise for the 
treatment of several subtypes of ataxia (Zesiewicz and Sullivan, 2008; Zesiewicz et al., 2009a; 
Zesiewicz 2009b; Zesiewicz et al., 2012). Varenicline is a partial agonist at α4β2, α3β4, α3β2, and 
α6-containing nAChRs and a full agonist at α7 receptors (Mihalak et al., 2006; Rollema et al., 
2007a; 2007b) and thus has activity at the receptor subtypes suspected to mediate the 
neuroprotective effects observed following treatment with nicotinic agonists (i.e. α4β2 and α7 
nAChRs).  
Preclinical studies have demonstrated that in animals with ataxia, chronic varenicline 
administration can improve performance on a rotorod and attenuate balance deficits on a beam, 
and similar results were found following chronic nicotine administration (Wecker et al., 2013). 
Additionally, nicotinic agonists have been shown to: decrease L-DOPA-induced dyskinesias in 
both rodent and non-human primate models of Parkinson's disease (Quik et al., 2007, 2013; 
2013b; Bordia et al 2008; Huang et al., 2011; Zhang et al., 2013), attenuate Δ9 -THC-induced 
ataxia in mice (Smith and Dar, 2007), attenuate motor abnormalities in a rodent model of tardive 
dyskinesia (Bordia et al., 2012), and reduce deficits associated with ethanol-induced ataxia in 
rodents (Taslim et al., 2008). Furthermore, a study from our laboratory demonstrated that 
chronic administration of nicotine to animals with olivocerebellar lesions could attenuate an 
impairment in a spatial gait parameter (Wecker et al., 2013). 
 It is as yet unknown which brain regions are involved in the observed improvements in 
motor function following the administration of nicotinic agonists. As discussed, patients with 
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some subtypes of cerebellar ataxia exhibit cerebellar degeneration, and thus modulation of 
nicotinic receptor signaling within the cerebellum may underlie improvements in motor function. 
Indeed, direct infusion of the α4β2 selective nicotinic agonist RJR-2403 into the cerebellum of 
mice has been shown to attenuate ethanol-induced ataxia (Taslim et al., 2008). However, 
patients with Parkinson’s disease have similar, but not identical, gait abnormalities as patients 
with cerebellar ataxia (Ebersbach et al., 1999), suggesting the involvement of other brain 
regions contributing to the gait dysfunction observed in patients with movement disorders.  
 
1.5. Role of the cholinergic system in gait dysfunction 
In conjunction with the cerebellum and other motor regions, control of gait and posture 
has been shown to be mediated by cholinergic neurons within the pedunculopontine nucleus 
(PPN) (Karachi et al., 2010). Furthermore, the loss of these cholinergic neurons has been 
correlated with the clinical severity of Parkinson’s disease (Rinne et al., 2008). Several clinical 
reports have documented that patients with lesions within the mesencephalic locomotor region, 
which contains the PPN, exhibit ataxia yet lack cerebellar lesions or other typical features of 
Parkinsonian gait (Hathout and Bhidayasiri, 2005; Bhidayasiri et al., 2003; Masdeu et al., 1994). 
Thus, evidence suggests that gait dysfunction in patients with movement disorders may not be 
attributed solely to cerebellar dysfunction. Since the PPN connects to numerous other brain 
regions involved in motor control and coordination including the cerebellum, motor cortex, and 
basal ganglia (Aravamuthan et al., 2007), it is plausible that the cholinergic neurons within the 
PPN may mediate the motor improvements observed following the administration of nicotinic 
agonists. In addition, these findings highlight the importance of clinical assessments of motor 
function to further elucidate similarities as well as differences among the brain regions affected 
and symptoms manifest in patients with movement disorders.   
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1.6. Clinical assessment of ataxia: use of a principal component analysis 
 For patients with ataxia, clinical assessments of motor deficits has historically been 
quantified using several scales including the Scale for the Assessment of Ataxia (SARA), 
International Cooperative Ataxia Rating Scale (ICARS), the Ataxia Functional Composite Scale 
(AFCS), and the Berg Balance Scale (BBS) (Trouillas et al., 1997a; Schmitz-Hubsch et al., 
2006a, 2006b; Berg et al., 1989). However, several of these scales can be subjective 
(Subramony et al., 2012), especially in patients with degenerative cerebellar disorders (Schmitz-
Hubsch et al., 2006b; Schoch et al., 2007). Furthermore, depending on their subtype of ataxia, 
these patients can vary in their symptoms and motor deficits, underscoring the inherent 
challenges in using these scales to quantify and compare deficits between patients, as well as 
in testing the effectiveness of therapies to improve these deficits. 
Due to the limitations of these scales, alternative quantitative tests have been employed 
to more objectively and reliably measure deficits in patients with ataxia. For example, 
temporospatial aspects of patients’ gait can be obtained using the GAITRite Walkway System 
(CIR Systems, Inc., PA, US), which can serve as a tool for monitoring disease progression and 
evaluating treatment effectiveness in patients (Hass et al., 2012). However, although gait 
analysis represents an important translatable assessment between preclinical and clinical 
studies, the inherent variability among patients with ataxia as well as the speed at which they 
ambulate can confound data interpretation among a population of patients. To address these 
concerns and control for these confounds, several clinical studies have used a principal 
component analysis (PCA) to calculate a gait index quantifying deviations from normal gait 
(Wren et al., 2007; Schwartz and Rozumalski, 2008; Gouelle et al., 2013; Schutte et al., 2000). 
Furthermore, although clinical studies have documented numerous gait alterations in patients 
with ataxia, it can be difficult to conceptualize the net result of changes in multiple gait 
parameters upon the overall gait cycle. This limitation is especially important due to the 
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interdependency of individual parameters upon the maintenance of the gait cycle, as alterations 
in several gait parameters may be due to a deficit in one key gait parameter.  
The use of a PCA can address these concerns as well, since by definition a PCA 
reduces redundancy in the dataset by identifying correlations between dependent variables and 
consolidating the useful information into several principal components that categorize the 
dataset (reviewed in Abdi and Williams, 2010). The first principal component extracted from this 
analysis explains the largest amount of variance within the data, and each consecutive 
component extracted explains less of the total variance remaining in the dataset. This 
information can then be used to weight the influence of each principal component upon the 
dataset to produce a gait index that conceptualizes the influence of small changes in individual 
parameters. While the method of developing a gait index from a PCA has not been used to 
assess gait in the ataxia population, it has been documented that ataxic patients exhibit large 
increases in gait variability from normal as a result of their symptoms, which is exacerbated at 
speeds slower or faster than a “comfortable” walking speed (Wuehr et al., 2013; Schniepp et al., 
2012). Thus, it is plausible that a gait index measuring deviations from normal gait may be 
useful in comparing results between animals and humans with ataxia. 
 
1.7. Summary 
In sum, numerous studies demonstrate the efficacy of nicotinic agonists for the treatment 
of neurodegenerative or motor disorders in animals, underscoring their potential benefit for the 
treatment of similar disorders in humans. As the mechanism underlying the effects of nicotinic 
agonists remains to be elucidated, the purpose of these experiments is to first investigate gait 
impairments in animals with ataxia using the DigiGait™ treadmill system.  
Ataxia was induced by the systemic administration of 3-acetylpyridine (3-AP), a 
competitive antagonist for Vitamin B3. Pyridines such as nicotinamide are important metabolites 
in the conversion of NAD+ to NADP+ for ATP synthesis within the Electron Transport Chain, and 
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3-AP irreversibly blocks this pathway, leading to cell death (Desclin and Escubi, 1974). While it 
is unknown why inferior olivary neurons in the rat are particularly susceptible to the neurotoxic 
effect of 3-AP, the administration of a large dose of nicotinamide 3.5 hours afterwards quenches 
3-AP toxicity, resulting in a selective lesion of the inferior olive (Seoane et al., 2005). 
As the goal of these studies is to provide translational results that may be of benefit to 
human studies, the translational potential of this method of gait assessment will be investigated 
by comparing gait impairments in rats with olivocerebellar lesions to those reported in humans 
with ataxia. These studies will also demonstrate whether the chronic administration of 
varenicline can attenuate any gait impairment manifest as a consequence of olivocerebellar 
lesions as well as whether varenicline’s effect could be blocked by the nicotinic antagonist 
mecamylamine, thereby further elucidating the mechanism by which varenicline can attenuate 
gait impairments in animals with olivocerebellar lesions. 
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Chapter Two: 
Gait analysis and the cumulative gait index (CGI): Translational tools to assess 
impairments exhibited by rats with olivocerebellar ataxia 
 
Note to reader: 
These results have been previously published (Lambert et al., 2014) and are presented with 
permission of the publisher. C.S. Lambert contributed to the execution and analysis of these 
studies as well as their preparation for publication. R.M. Philpot and L. Wecker contributed to 
the design, analysis, and preparation of this study for publication. B.E. Johns, M.E. Engberg, 
and S.H. Kim contributed to data analysis and manuscript editing. 
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2.1 Abstract 
Deviations from ‘normal’ locomotion exhibited by humans and laboratory animals may be 
determined using automated systems that capture both temporal and spatial gait parameters. 
Although many measures generated by these systems are unrelated and independent, some 
may be related and dependent, representing redundant assessments of function. To investigate 
this possibility, a treadmill-based system was used to capture gait parameters from normal and 
ataxic rats, and a multivariate analysis was conducted to determine deviations from normal. 
Rats were trained on the treadmill at two speeds, and gait parameters were generated prior to 
and following lesions of the olivocerebellar pathway. Control (non-lesioned) animals exhibited 
stable hindlimb gait parameters across assessments at each speed. Lesioned animals exhibited 
alterations in multiple hindlimb gait parameters, characterized by significant increases in stride 
frequency, braking duration, stance width, step angle, and paw angle and decreases in stride, 
stance, swing and propulsion durations, stride length and paw area. A principal component 
analysis of initial hindlimb measures indicated three uncorrelated factors mediating 
performance, termed Rhythmicity, Thrust and Contact. Deviation in the performance of each 
animal from the group mean was determined for each factor and values summed to yield the 
cumulative gait index (CGI), a single value reflecting variation within the group. The CGI for 
lesioned animals increased 2.3-fold relative to unlesioned animals. This study characterizes gait 
alterations in laboratory rats rendered ataxic by destruction of the climbing fiber pathway 
innervating Purkinje cells and demonstrates that a single index can be used to describe overall 
gait impairments. 
Keywords 
Ataxia, treadmill gait analysis, olivocerebellar-lesioned rats, DigiGait™ Imaging System 
Abbreviations 
CGI: Cumulative Gait index; PCA: Principal Component Analysis 
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2.2. Introduction 
Gait analysis has been used for more than 30 years to assess the effects of physical and 
chemical perturbations on walking and running in laboratory animals (de Medinaceli et al., 1982; 
Mullenix et al., 1975). Initial assessments were conducted using the ‘painted footprint’ 
procedure, and typically provided measures of stride length and stance width. This led to the 
development of a basic apparatus that extended measures to include stride frequency and 
velocity (Clarke et al., 1986). Since that time, several systems have been developed that 
provide information at different walking speeds, critical for understanding both coordination and 
balance, as well as for assessing the efficacy of possible therapeutic regimens for movement 
disorders (Tang and Su, 2013). 
Results from studies to date characterizing gait alterations in ataxic laboratory animals 
are difficult to reconcile because of two confounds, viz., the effect of speed on gait parameters 
and the interdependency of gait parameters. For example, although increased hindpaw stance 
width has been shown to be manifest by two unrelated transgenic ataxic mouse models (Duvick 
et al., 2010; Maity et al., 2012), this alteration was not present in other studies using a ‘Lurcher-
like’ mouse or following cerebellar lesions (Stroobants et al., 2013; Cops et al., 2013). A careful 
analysis of these studies indicates that for the former, animals were tested at a treadmill speed 
of 35 cm/s, whereas for the latter, animals were run at 22 and 15 cm/s, respectively. The idea 
that walking speed is a prime consideration determining gait parameters is underscored by 
evidence that gait alterations in Lurcher mice, who walk considerably slower than their wild-type 
counterparts (<15 cm/s compared with >25 cm/s), were obviated when walking speed was 
taken into account (Cendelin et al., 2010). 
In addition to speed, the interdependency of gait parameters must also be considered. 
Although laboratory animal studies have not addressed this issue, clinical studies have 
indicated that many gait parameters are highly related and interdependent, and may represent 
similar aspects of the same general function (Goulle et al., 2013). To isolate and identify 
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combinations of gait parameters that are strongly associated with the variance in the data, but 
are uncorrelated to one another, a principal component analysis (PCA) may be used. Although 
the mathematics of this process are complex (Abdi and Williams, 2010; Jolliffe, 2002; Ringer, 
2008), the purpose of a PCA is to reduce the dimensionality of a data set consisting of several 
interrelated variables, while retaining the variation present in the data (Jolliffe, 2002; Ringer, 
2008). Thus, redundant aspects of the original data set are consolidated into a smaller number 
of principal components. Clinicians have used PCA to analyze gait and have demonstrated that 
16 independent gait parameters could be used to describe gait patterns in humans, and based 
on these values, a ‘normalcy index’ could be calculated that reflected gait patterns that deviated 
from normal (Schutte et al., 2000), a concept that has been validated (Wren et al., 2007) and 
extended (Schwartz and Rozumalski, 2008) in the clinical literature. A similar strategy has not 
been applied to laboratory animal studies, an approach that would be highly beneficial for 
translational investigations. 
Therefore, the goals of this study were to: characterize gait abnormalities in 
olivocerebellar-lesioned rats; use a PCA to identify independent aspects of gait performance; 
calculate a single quantifiable index of gait; and determine how this index is altered following 
destruction of the olivocerebellar pathway. To accomplish this, the DigiGaitTM Imaging System 
(Mouse Specifics, Boston, MA) was used to determine temporal and spatial gait parameters in 
normal rats and rats rendered ataxic following olivocerebellar lesions (Wecker et al., 2013). 
Although this system has been used to assess gait parameters in rats following spinal cord 
injury (Ek et al., 2010; Springer et al., 2010; Redondo-Castro et al., 2013), peripheral nerve 
injury or inflammation (Piesla et al., 2009; Rittenhouse et al., 2011), and damage to the brain 
(Russell et al., 2011; Rane and King, 2011), this is the first study to describe a single index 
reflecting gait pattern impairment in laboratory rats rendered ataxic by destruction of the 
climbing fiber pathway innervating Purkinje cells. 
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2.3. Materials and Methods 
2.3.1. Animals and lesions 
Male Sprague-Dawley rats (225–250 g and 52–60 days old, Harlan Industries, 
Indianapolis, IN) were acclimated to the vivarium for 1 week and housed two per cage in a 
temperature- and humidity-controlled vivarium on a 12:12 h (7 am:7 pm) light-dark cycle; 
experiments were conducted between 10 am and 2 pm to minimize variability in behavior. The 
care and use of animals were approved in accordance with guidelines set by the University of 
South Florida Institutional Animal Care and Use Committee and the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals. 
Lesions of the olivocerebellar pathway were induced by the administration of 3-
acetylpyridine (3-AP; 70 mg/kg, i.p.) followed by an injection of nicotinamide (300 mg/kg, i.p.) 
3.5 h later; chemicals were obtained from Sigma-Aldrich Co. (St. Louis, MO). This injection 
paradigm has been demonstrated to localize the resulting neurotoxicity primarily to the inferior 
olive, with weak effects on other brain regions involved in motor control (Seoane et al., 2005; 
Llinas et al., 1975; Sotelo et al., 1975). In addition, studies in our laboratory have demonstrated 
that this injection paradigm leads to the loss of 85% of inferior olivary neurons in rats, and 
results in impaired performance on the rotorod, balance beam, and in the open field (Wecker et 
al., 2013). 
 
2.3.2. Apparatus and behavioral paradigm 
Prior to initial recordings, rats were trained on the DigiGaitTM treadmill for 5 consecutive 
days. Preliminary studies indicated that a speed of 25 cm/s represented a ‘comfortable’ walking 
speed for rats, in general agreement with prior reports (Gillis and Biewener, 2001; Laughlin and 
Armstrong, 1982). Further, initial studies indicated that at a lower speed of 15 cm/s, rats did not 
perform adequately for gait analysis, whereas at a more challenging speed of 35 cm/s, 
representing a fast walk, performance was consistent; speeds faster than 35 cm/s may have 
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been too challenging for animals with olivocerebellar lesions to walk consistently for analysis 
purposes (unpublished observations). Each training day consisted of a single 2 min trial at each 
speed, with trials separated by 1–2 h, and with the lower speed always run first. The treadmill 
belt and enclosure were wiped with 70% ethanol between each trial. 
For training, each animal was secured inside the apparatus and the treadmill was started 
immediately at 25 cm/s. For training at 35 cm/s, the treadmill belt was started at 25 cm/s, and 
increased to 35 cm/s at a rate of 1 cm/s. A majority of animals exhibited rhythmic gait, and 
quickly learned to walk comfortably on the treadmill, while some animals did not walk 
adequately, and exhibited avoidance behaviors, such as turning or rearing. When this occurred, 
these behaviors were corrected by ‘nudging’ the animals using the plastic bumper at either end 
of the apparatus, changing the direction of the treadmill, or slowing the treadmill speed followed 
by gradually increasing it as the animal learned the task. 
Initial behavioral assessments were conducted 2 days following completion of training. 
Rats were placed in the apparatus and a 2 min trial at both speeds was recorded. Animals who 
did not complete a minimum of six uninterrupted strides at either 25 or 35 cm/s were retested at 
that speed. At 2 days following initial recordings, animals meeting criteria were assigned 
randomly to either unlesioned (control) or lesioned groups (Fig. 2.1), with a balanced distribution 
of ages within each group. The unlesioned group was used to ascertain the stability of gait 
parameters over time, thereby detecting any alterations that may have occurred as a 
consequence of acclimation or habituation to the apparatus. Animals in the lesioned group 
received injections of 3-AP/nicotinamide. All animals were reassessed 7 days later for 2 min at 
both speeds. 
 
2.3.3. Data capture and analysis 
DigiGaitTM Imaging software (version 12.2) was used to generate temporal and spatial 
gait parameters. The videos generated by the system were analyzed by a rater blinded to the 
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group assignment of each animal. Sequences for analysis were chosen by the blinded rater 
based on: the positioning of the animal relative to the boundaries of the apparatus to ensure that 
the gait of the animal was unimpeded; and the ability of the rater to clearly discern all 4 paws. 
The number of sequences containing ≥ 6 but ≤ 11 strides within a 2 min trial was counted, i.e., 
animals completing 12 consecutive strides completed two sequences. Approximately 5% of all 
animals (three animals) walked throughout the entire 2 min trial; the remaining animals walked 
sporadically throughout the trial, typically completing between 10 and 20 six-stride sequences 
within each trial. Strides were not counted when animals were in contact with the plastic 
bumpers, when animals were hopping, or when the speed of the treadmill was increased from 
25 to 35 cm/s. Data were analyzed using a one-way analysis of variance (ANOVA), with 
Dunnett’s test post hoc to compare final and initial assessments. 
Although the DigiGaitTM system generated more than 40 indices of gait dynamics and 
posture, the measures analyzed included stride duration, stride frequency, stance duration, 
swing duration, braking duration, propulsion duration, step angle, stride length, stance width, 
paw angle, and paw area (Fig. 2.2). In addition, the software calculates the variability associated 
with each spatial parameter, which was also included for analysis; percentages and ratio 
calculations were not included for analysis. A representative sequence was chosen for analysis, 
6–8 strides within this sequence were analyzed, and an average value generated for each 
parameter. Data indicated that the lesion affected gait parameters in both forelimbs and 
hindlimbs, albeit the magnitude of change for most parameters was greater in the latter, in 
agreement with our prior study (Wecker et al., 2013). In addition, for control rats, not all forelimb 
gait parameters were stable across measurements, likely reflecting the dual functionality of the 
forelimbs, which are involved not only in ambulation, but also in tactile sampling and gaining 
proprioceptive information (Clarke, 1995); thus, only values generated from hindlimbs were 
reported. Further, left and right hindlimb parameters did not differ significantly (p > 0.05 as per 
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paired t-tests) at each speed or assessment timepoint, indicating that gait was symmetrical, and 
thus, measures from right and left hindlimbs were pooled 
Data obtained from controls or animals subsequently lesioned with 3-AP were analyzed 
by a 2 × 2 repeated measures ANOVA with treadmill speed (25 and 35 cm/s) and assessment 
(initial and final) as variables. Subsequently, independent t-tests were used to investigate 
differences between treadmill speeds, and paired samples t-tests were used to determine 
differences between timepoints. 
A PCA was performed to determine whether the individual components of gait were 
interrelated and whether redundant aspects of the original data set could be consolidated into 
principal components. This analysis provided and isolated combinations of the original 
measures that were uncorrelated, representing distinct components of the data set. Varimax 
rotation was used to derive orthogonal factor scores and the minimum Eigenvalue for extraction 
was set at 1. Factor loadings were analyzed using data from both treadmill speeds, and items 
that met a minimum loading of ≥ ±0.5 were considered relevant. The cumulative gait index (CGI) 
was determined as described (Schutte et al., 2000) with minor modification. Briefly, the mean 
(μ) and standard deviation (σ) of each measure, at each speed, were determined using the 
initial values from all animals in the study. A Z-transformation (X - μ/σ) was applied to the data 
from each animal at both speeds and assessment timepoints. To generate the individual factor 
values, the associated factor loadings (α) derived from the PCA were used to weight the Z-
transformed data and these values were summed and the absolute value taken (|Σαz|). The 
resulting values were averaged across speeds to generate a factor value at each assessment 
timepoint. These factor values were summed to yield the CGI, representing the total deviation 
from typical gait for each animal. Individual factors and the CGI were analyzed by a mixed factor 
ANOVA with assessment as a repeated measure; Tukey’s test was used post hoc to ascertain 
group differences. 
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Correlational analyses (Pearson’s r) at each assessment timepoint and each treadmill 
speed were used to determine whether there were any relationships among gait parameters, as 
well as whether treadmill speed and/or 3-AP administration altered these relationships. 
Statistical analyses were performed using GraphPad Prism version 6.0 (GraphPad 
Software, Inc., San Diego, CA) and SPSS version 21.0 (SPSS Inc., Chicago, IL). A level of p < 
0.05 was accepted as evidence of a significant effect. 
 
2.4. Results 
2.4.1. Ability to walk on the treadmill 
A total of 63 animals were subjected to the 5 day training procedure and underwent 
initial assessment. At this time, three rats would not walk on the treadmill at either speed, one 
rat would not walk at 35 cm/s, and three rats failed to complete at least one sequence 
containing 6–11 strides at both speeds. Thus, seven of the rats were not used for further study 
because they failed to meet criteria upon initial assessment. The 56 remaining animals were 
assigned to either the unlesioned (n = 11) or lesioned (n = 45) groups with the latter containing 
four times as many animals as the former because a wide range of behavioral deficits occurs as 
a consequence of the lesion (Wecker et al., 2013). 
To determine whether the ability of animals to walk on the treadmill was stable over time 
and whether the lesion affected walking ability, the number of sequences containing 6–11 
uninterrupted strides within each trial was counted. The number of sequences upon initial 
assessment ranged from 1–31 at 25 cm/s and 1–44 at 35 cm/s, with averages of 11 and 18, 
respectively (Fig. 2.3). For unlesioned animals, performance was stable over time. For lesioned 
rats, 7/45 and 4/45 animals did not complete a 6–11 stride sequence at treadmill speeds of 25 
and 35 cm/s, respectively. The remaining animals (38 at 25 cm/s and 41 at 35 cm/s) exhibited 
significantly (p < 0.05) fewer sequences at both 25 cm/s [F (3,105) = 3.173] and 35 cm/s [F 
(3,108) = 14.19] with 34% and 54% decreases relative to initial values, respectively. Based on 
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studies demonstrating reduced locomotor activity of these animals in the open field (Wecker et 
al., 2013), it is likely that this decreased number of step sequences reflects a performance 
deficit and not a lack of compliance. The 11 animals that did not complete a 6–11 stride 
sequence at either speed (see above) did complete a 3–5 stride sequence. Analysis of gait 
parameters generated from these truncated sequences indicated that they did not differ 
significantly (p > 0.05) from those generated by animals who completed 6–11 uninterrupted 
strides. Thus, data were pooled for analyses of gait parameters. 
 
2.4.2. Effects of treadmill speed on gait parameters 
Unlesioned (control) animals were studied to determine the effects of treadmill speed on 
gait, ascertain whether gait measures were stable over time, and characterize the gait cycle in 
these rats. Results of a 2 × 2 repeated measures ANOVA revealed a significant (p < 0.05) main 
effect of speed on five temporal parameters (Fig. 2.4A). Increasing treadmill speed from 25 to 
35 cm/s resulted in a 21% increase in stride frequency [F (1, 10) = 109.8], an 18% decrease in 
stride duration [F (1, 10) = 102.2], a 23% decrease in stance duration [F (1, 10) = 88.8], a 28% 
decrease (reflecting a 21% decrease for initial and a 34% decrease for final assessments) in 
braking duration [F (1, 10) = 12.6], and a 21% decrease in propulsion duration [F (1, 10) = 50.8]; 
there was no difference between swing duration at 25 cm/s and 35 cm/s (data not shown). 
Although each of these parameters was altered by treadmill speed, the relative proportion of 
time spent in each phase of the gait cycle was constant (Fig. 2.4). Additionally, a 2 × 2 repeated 
measures ANOVA indicated a significant (p < 0.05) main effect of assessment timepoint (initial 
vs final) at 35 cm/s for stride frequency [F (1, 10) = 5.15] and braking duration [F (1, 10) = 8.00], 
with a 4% decrease for the former and a 22% decrease for the latter. 
The spatial parameters significantly (p < 0.05) affected by speed (Fig. 2.4B) were stride 
length, which increased by 16% [F (1, 10) = 76.3], stance width, which decreased by 9% [F 
(1,10) = 9.07), and step angle, which decreased by 22% [F (1, 10) = 8.20]. Although paw angle 
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decreased by 15%, this was not significant; paw area was unaltered. There was no main effect 
of speed on the calculated variability for stride length, stance width, step angle, paw angle, or 
paw area. In addition, there was a significant (p < 0.05) main effect of assessment timepoint on 
paw angle variability at both speeds [F (1, 10) = 9.81]. At 25 cm/s, paw angle variability 
increased 55% from 5.3 ± 0.3 to 8.2 ± 0.9 [t (10) = 3.20] and at 35 cm/s, paw angle variability 
increased 53% from 5.9 ± 0.5 to 9.0 ± 1.1 [t (10) = 2.63]. 
 
2.4.3. Effects of 3-AP on gait parameters 
The effects of olivocerebellar lesions induced by the administration of 3-AP on gait are 
shown in Fig. 2.5. Results of a 2 × 2 (speed × assessment) repeated measures ANOVA 
indicated that the effects of 3-AP were independent of treadmill speed, i.e., there was no 
interaction. The following significant (p < 0.05) temporal alterations were apparent across 
speeds: an 9% increase in stride frequency [F (1,44) = 32.2]; an 8% decrease in stride duration 
[F (1,44) = 29.4]; a 10% decrease in stance duration [F (1,44) = 38.6]; a 27% increase in 
braking duration [F (1,44) = 33.6]; and a 17% decrease in propulsion duration [F (1,44) = 60.5]. 
In addition, the lesion led to a 6% decrease in swing duration [F (1,44) = 4.11] from 138 to 131 
ms and from 135 to 126 ms at 25 cm/s and 35 cm/s, respectively. Thus, the relative proportion 
of the gait cycle in the braking phase increased from an average of 11% to 16%, while that in 
the propulsion phase decreased from an average of 59% to 53%, indicating that impaired 
animals required greater time to achieve maximal paw contact during braking. 
The spatial measures significantly (p < 0.05) altered by the lesion included: an 8% 
decrease in stride length [F (1,44) = 33.8]; a 25% increase in stance width [F (1,44) = 81.6]; a 
32% increase in step angle [F (1,44) = 28.0]; a 233% increase in paw angle [F (1,44) = 162.6]; 
and a 25% decrease in paw area [F (1,44) = 176.4]. In addition, paw angle variability increased 
significantly [F (1, 44) = 159.3, p < 0.05] at both speeds. At 25 cm/s, paw angle variability 
increased by 160% from 5.8 ± 0.3 to 15.1 ± 0.9 [t (44) = 9.62] and at 35 cm/s paw angle 
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variability increased by 171% from 5.5 ± 0.3 to 14.9 ± 0.9 [t (44) = 9.97]. Paw area variability 
also increased significantly [F (1, 44) = 9.43, p < 0.05] by 26% at 25 cm/s from 0.35 ± 0.03 to 
0.44 ± 0.03 [t (44) = 2.67] and by 18% at 35 cm/s from 0.34 ± 0.02 to 0.40 ± 0.02 [t (44) = 2.12]; 
stance width and stride length variability were unaffected. Thus, as a result of the lesion, 
animals had shorter strides, established a wider base of support, had a large and highly variable 
increase in lateral paw splay, and exhibited less stride-to-stride consistency in the orientation of, 
and contact made by, the hindpaws. 
 
2.4.4. PCA and the cumulative gait index (CGI) 
To produce a single measure of gait impairment similar to the indices used for clinical 
populations (Gouelle et al., 2013; Schutte et al., 2000; Schwartz and Rozumalski, 2008), the six 
temporal and five spatial gait parameters analyzed were subjected to a PCA to obviate 
redundant aspects of the original data set and ascertain whether the information could be 
consolidated into a smaller number of principal components. This analysis indicated that three 
factors accounted for 72% of the total variance in the data, explaining more variability in the 
data than any single gait parameter (see Table 2.1). 
The first factor (e = 4.254), which was termed Rhythmicity, encompassed the temporal 
parameters stride duration, stride frequency, stance duration and propulsion duration, but did 
not include braking or swing durations, both of which were more associated with the second 
factor. This indicates that stride duration, stride frequency, stance duration and propulsion 
duration are interdependent components of gait cycle timing, whereas braking and swing 
duration are somewhat independent of overall stride time. Further, the valences of the loading 
values indicate that Rhythmicity increases as stride, stance and propulsion durations increase 
and stride frequency decreases. 
The second factor (e = 2.406), which was termed Thrust, included braking and swing 
durations, as well as stride length, stance width and step angle; although paw angle was 
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positively associated with this factor, it had a greater association with the third factor. Thus, 
Thrust involves regulating trajectory and momentum through adjustments in the advancement 
and placement of the hindlimbs. The loading valences for Thrust parameters indicate that this 
factor increases as braking duration, stance width, and step angle increase and swing duration 
and stride length decrease. The third factor (e = 1.254), termed Contact, contained paw angle 
and paw area, and loading valences indicated that Contact increases with increasing paw angle 
and decreasing paw area. 
To determine whether the variability within the population was affected by the lesion, the 
absolute deviation from the mean for each factor for each animal was determined, and values 
summed to yield the CGI (Fig. 2.6). A mixed factor ANOVA indicated that the CGI for unlesioned 
animals did not change significantly over time, whereas the CGI for lesioned animals increased 
2.7-fold (p < 0.05) relative to the initial assessment, and 2.3-fold (p < 0.05) relative to the final 
assessment for unlesioned animals [F (1,54) = 18.7]. Further, this difference reflected an 
increased absolute deviation for all three factors and differed significantly (p < 0.05) from final 
assessments for unlesioned rats [Rhythmicity: F (1,54) = 6.57; Thrust: F (1,54) = 19.5; Contact: 
F (1,54) = 9.47]; the deviations of the three factors did not change over time for unlesioned 
animals. 
 
2.4.5. Effects of 3-AP on parameter relationships 
To determine whether the lesion affected relationships among gait parameters, 
correlations were calculated at each speed prior to and following the administration of 3-AP. The 
lesion did not change relationships involving swing and braking durations, stance width or step 
angle (data not shown). The only relationships significantly (p < 0.05) altered were those 
involving paw angle and paw area, i.e., components of Contact. Following the administration of 
3-AP, paw angle correlated significantly (p < 0.05) with stance duration, stride duration, stride 
length and stride frequency at both speeds, correlations that were not present during the initial 
37 
 
assessment (Table 2.2). Further, there was a negative correlation between paw angle and 
propulsion duration for the initial assessment that was not affected by 3-AP. In contrast, paw 
area correlated significantly (p < 0.05) with stance duration, stride duration, stride length and 
stride frequency only at 25 cm/s; the correlations at 35 cm/s did not reach significance. Further, 
3-AP altered the relationship (p < 0.05) between paw area and propulsion duration at both 
speeds. These results indicate that the lesion not only affects individual parameters of gait, but 
in several cases, alters the relationships among these parameters. 
 
2.5. Discussion 
2.5.1. 3-AP induced gait alterations and the CGI 
The present study characterized alterations in temporal and spatial gait parameters at 
two speeds in a rodent model of olivocerebellar ataxia, determined how the relationships 
between gait parameters were altered in ataxic animals, and quantified the severity of 
impairment across multiple measures of gait using a single index. Results indicated that 
increasing treadmill speed resulted in significant changes in all temporal gait parameters, as 
well as the spatial parameters of stride length, stance width and step angle. For unlesioned 
animals, performance was stable across the 9 days of assessment at each treadmill speed. 
Further, when treadmill speed increased, animals compensated by shortening the braking and 
propulsion durations of the stance phase, and by increasing stride length, alterations that 
contributed to all other gait parameter changes. Lesions of the inferior olive produced significant 
changes in multiple gait parameters that were apparent at both treadmill speeds. These 
alterations included increases in stride frequency, braking duration, stance width, step angle, 
and paw angle and decreases in stride, stance, propulsion and swing durations, as well as 
stride length and paw area. 
A PCA, performed on gait measures from normal, healthy (unimpaired) animals to 
capture independent aspects of gait performance on the treadmill, identified three factors 
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termed Rhythmicity, Thrust, and Contact. Rhythmicity encompassed temporal parameters 
(stride frequency, propulsion duration, and stance and stride durations), Thrust was composed 
of both temporal (swing and braking durations) and spatial (stride length, stance width, and step 
angle) parameters, and Contact reflected paw angle and area. For each of these factors, 
lesioned animals exhibited a 2–3 fold increased deviation from typical gait. Further, the CGI, 
which represents the total deviation from typical gait for all gait measures as determined by 
summation of the deviations for the three independent factors increased 2.7-fold following the 
lesion. This representation of the overall magnitude of gait impairment has been recognized by 
clinicians and used to assess gait impairments in humans (Schutte et al., 2000; Wren et al., 
2007; Schwartz and Rozumalski, 2008). Using a PCA to identify related measures and 
consolidate deviations from typical gait minimizes redundancy in the data and provides a single 
measure that is highly sensitive to changes in performance. Further, the CGI may have greater 
translational value than any single gait measure when assessing impairment and subsequent 
treatment effects because individual gait measures may or may not represent the same deficit 
across species and different species may express the same underlying deficit on different 
measures. This is the first study to apply this approach to laboratory animals. 
 
2.5.2. Comparison to assessments in animal models of ataxia 
Although numerous studies have investigated gait alterations in mouse models of ataxia, 
the present study represents the first to characterize both temporal and spatial gait alterations in 
a rat following olivocerebellar lesions. Prior studies in our laboratory have shown that following 
the administration of 3-AP, rats exhibit shorter latency to fall from the rotorod, increased time 
required to cross a stationary beam, decreased velocity and distance moved in the open field, 
and increased stance width and decreased stride length for both hindlimbs and forelimbs during 
unforced locomotion (Wecker et al., 2013). The present study extends these findings to include 
forced locomotion, and detected multiple alterations in gait measures with hindlimbs exhibiting 
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larger alterations than forelimbs for most parameters. Because rats produce greater ground 
reaction force in the hindlimbs relative to the forelimbs (Clarke et al., 1997; Muir and Whishaw, 
2000), with hindlimbs providing most of the early braking and supportive forces during 
locomotion (Clarke, 1995), gait alterations in hindlimbs are similar to changes observed in 
humans (Stolze et al., 2002). The finding that olivocerebellar lesions affected gait parameters 
during both forced and unforced or ‘natural’ movement agrees with results from studies 
investigating two unrelated transgenic ataxic mouse models that demonstrated gait alterations 
for both hindlimbs and forelimbs at speeds of either 15 cm/s or 35 cm/s, respectively (Maity et 
al., 2012; Cops et al., 2013). In addition, the 32% increase in step angle following 3-AP 
administration (Figure 5B) is consistent with ethanol-induced ataxia in rats (Hannigan and Riley, 
1988). [It is critical to note that version 12.5 (and all previous versions) of the DigiGaitTM 
software calculates the complementary angle of the step angle as defined by Hannigan and 
Riley (1988). Thus, the output from the program was subtracted from 90◦ to reflect the angle 
commonly referred to in the literature as step angle.] 
Although studies have reported that stride length variability is increased in mice with 
cerebellar lesions (Stroobants et al., 2013), we did not detect any alterations in this measure in 
olivocerebellar lesioned rats. This difference may be attributed to methodology because the 
data for the former was based on a single trial following a 30 s habituation to the apparatus 
(Stroobants et al., 2013), whereas data collected in the present study represented a sample of 
the animal’s best performance, and was dependent upon animals engaging in sustained walking 
for at least six successive strides. 
 
2.5.3. Comparison of gait alterations between olivocerebellar lesioned rats and humans with 
ataxic disorders 
Several gait alterations exhibited by rats following destruction of the climbing fiber 
pathway by 3-AP are very similar to those observed in patients with ataxic disorders. Studies 
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have demonstrated that, compared to healthy control subjects, ataxic patients exhibit shorter 
stride lengths (Palliyath et al., 1998; Morton and Bastian, 2003; Mari et al., 2012; Serrao et al., 
2013) and larger stance widths (Stolze et al., 2002; Mari et al., 2012; Serrao et al., 2013; 
Hudson and Krebs, 2000; Ilg et al., 2007) during walking or turning, results similar to those in 
rats with olivocerebellar lesions. Further, the delayed heel-off time (i.e., approximately the 
beginning point of propulsion) and decreased duration from heel-off to toe-off observed in ataxic 
patients (Palliyath et al., 1998) are highly similar to the increased braking duration and 
decreased propulsion duration, respectively, exhibited by rats following the administration of 3-
AP. In addition, analysis of gait in patients with cerebellar disease using a treadmill system 
detected an increased foot angle splay (Stolze et al., 2002), similar to that in lesioned rats. 
Increased variability of gait parameters is often described in patients with cerebellar 
lesions (Palliyath et al., 1998; Ilg et al., 2007; Schniepp et al., 2012; Wuehr et al., 2013). 
Although stride length and stance width variability exhibited by the rats were unaffected by the 
lesion, paw angle variability was three times greater in lesioned than in unlesioned animals. This 
finding, as well as the increase in paw area variability, indicates that paw placement was less 
consistent following the lesion. Interestingly, stance width variability was unaltered by the lesion, 
similar to that reported for patients with cerebellar ataxias (Palliyath et al., 1998; Wuehr et al., 
2013), perhaps reflecting a consistent maximal increase in base support as a compensatory 
mechanism. In contrast, stride length variability was unaltered in lesioned animals, whereas it is 
increased in patients with cerebellar ataxia (Palliyath et al., 1998). The difference between our 
findings and those in the clinical literature may reflect differences in performance speed. Studies 
indicate that gait variability in ataxic patients is strongly dependent on walking speed (Schniepp 
et al., 2012; Wuehr et al., 2013), with minimal variability at the preferred speed of each 
individual (Wuehr et al., 2013). The present study was conducted during forced locomotion, 
which may obviate variability relative to spontaneous ambulation. Nevertheless, the overall 
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similarities in gait alterations in the present study and those from the human literature 
underscore the translational nature of this study and this method of gait assessment. 
 
2.6. Conclusions 
Rats rendered ataxic following olivocerebellar lesions exhibit alterations in several 
hindpaw gait parameters that are similar to gait alterations observed in the clinical population of 
ataxic patients. The use of multivariate analysis to yield a single measure of gait impairment, the 
CGI, provides a sensitive and reliable indicator applicable to studies in laboratory animals. This 
method of assessment should be more useful than quantifying individual gait parameters when 
engaging in translational studies to develop treatment interventions. 
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2.8. Figures and Tables 
 
 
 
 
 
  
 
Fig. 2.1. Experimental paradigm. Rats were trained to walk on the DigiGaitTM system at 25 and 
35 cm/s for 5 consecutive days. Initial behavioral assessments were conducted 2 days following 
training by recording baseline performance for 2 min at both speeds. At 2 days following initial 
recordings, animals were assigned randomly to either unlesioned (control) or lesioned groups, 
and the latter received injections of 3-AP/nicotinamide. All animals were reassessed 7 days later 
for 2 min at both speeds. 
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Fig. 2.2. Representation of gait parameters. Diagrammatic representation of temporal and 
spatial gait parameters analyzed. 
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Fig. 2.3. Effects of olivocerebellar lesions on treadmill performance. The number of 
uninterrupted sequences containing 6–11 strides within a 2 min segment at treadmill speeds of 
[A] 25 cm/s and [B] 35 cm/s were determined at baseline (initial assessment) and 9 days later 
(final assessment) for both unlesioned and 3-AP lesioned animals. Bars represent mean values 
+ s.e.m.; the number of animals per group is shown in parentheses. The asterisks denote 
significant (p < 0.05) differences. 
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Fig. 2.6. Resultant PCA factors and the cumulative gait index. The three factors generated by 
the PCA (Rhythmicity, Thrust and Contact) and the CGI were analyzed across timepoints. Bars 
represent mean values + s.e.m. with an n = 56 for initial assessments representing the total 
population, n = 11 for the unlesioned group and n = 45 for the lesioned group. Data were 
compared using a one-way ANOVA. The asterisks denote significant (p < 0.05) differences from 
all other groups as determined by Tukey’s test. 
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Table 2.1. Principal Component Analysis at Baseline. Gait parameters from the initial 
assessment for all animals (n = 56) were used for a principal component analysis. Factor 
loadings > 0.5 are bolded, representing primary components of the factor. 
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Table 2.2. Effects of 3-AP on Relationships Among Gait parameters. Correlation coefficients 
(Pearson’s r) denoting the relationship among gait parameters at eachs peed prior to (initial) 
and following (final) the administration of 3-AP; significant (p < 0.05) correlations are bolded. 
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Chapter Three: 
Analysis of gait in rats with olivocerebellar lesions and ability of the nicotinic 
acetylcholine receptor agonist varenicline to attenuate impairments 
 
 
Note to reader: 
These results have been previously published (Lambert et al., 2015) and are presented with 
permission of the publisher. C.S. Lambert contributed to the execution and analysis of these 
studies as well as their preparation for publication. R.M. Philpot and L. Wecker contributed to 
the design, analysis, and preparation of this study for publication. B.E. Johns and M.E. Engberg, 
contributed to data analysis and manuscript editing. 
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3.1. Abstract 
Studies have demonstrated that administration of the neuronal nicotinic receptor agonist 
varenicline to rats with olivocerebellar lesions attenuates balance deficits on a rotorod and 
balance beam, but the effects of this drug on gait deficits have not been investigated. To 
accomplish this, male Sprague–Dawley rats were trained to walk on a motorized treadmill at 25 
and 35 cm/s and baseline performance determined; both temporal and spatial gait parameters 
were analyzed. A principal component analysis (PCA) was used to identify the key components 
of gait, and the cumulative gait index (CGI) was calculated, representing deviations from 
prototypical gait patterns. Subsequently, animals either remained as non-lesioned controls or 
received injections of 3-acetylpyridine (3-AP)/nicotinamide to destroy the climbing fibers 
innervating Purkinje cells. The gait of the non-lesioned group was assessed weekly to monitor 
changes in the normal population, while the gait of the lesioned group was assessed 1 week 
following 3-AP administration, and weekly following the daily administration of saline or 
varenicline (0.3, 1.0, or 3.0 mg free base/kg) for 2 weeks. Non-lesioned animals exhibited a 60–
70% increased CGI over time due to increases in temporal gait measures, whereas lesioned 
animals exhibited a nearly 3-fold increased CGI as a consequence of increases in spatial 
measures. Following 2 weeks of treatment with the highest dose of varenicline (3.0 mg free 
base/kg), the swing duration of lesioned animals normalized, and stride duration, stride length 
and step angle in this population did not differ from the non-lesioned population. Thus, 
varenicline enabled animals to compensate for their impairments and rectify the timing of the 
gait cycle. 
Keywords 
Ataxia, varenicline, gait, principal component analysis, cumulative gait index 
Abbreviations 
3-AP: 3-acetylpyridine; CGI: Cumulative Gait Index; PCA: Principal Component Analysis 
 
54 
 
3.2. Introduction 
Ataxia represents an array of symptoms including uncoordinated voluntary movements 
and deficits in balance, locomotion and gait. These characteristics typically manifest as a result 
of cerebellar dysfunction that can be inherited, idiopathic or result from a stroke, traumatic brain 
injury, lesion, or chemical insult to the brain (Perlman, 2000). Thus, the symptoms and deficits 
manifest can vary considerably among patients. Presently, there are no approved treatments for 
ataxia, although evidence suggests that modulation of the nicotinic cholinergic system within the 
central nervous system may provide therapeutic benefit. 
Both preclinical and clinical studies have shown that nicotinic cholinergic agonists are 
effective in reducing motor abnormalities associated with several disorders. Nicotine has been 
shown to potentiate haloperidol-induced hypokinesia and catalepsy in rodent models of 
Tourette’s syndrome (Elazar and Paz, 1999; Dursun et al., 1994), and decreases motor tics in 
patients with this disorder (Dursun et al., 1994; Silver et al., 1996; Dursun and Kutcher, 1999). 
Several nicotinic agonists have also been shown to decrease L-DOPA-induced dyskinesias in 
both rodent and non-human primate models of Parkinson’s disease (Quik et al., 2013; Quik et 
al., 2007; Bordia et al., 2008; Huang et al., 2011; Zhang et al., 2014; Zhang et al., 2013), motor 
abnormalities in a rodent model of tardive dyskinesia (Bordia et al., 2012), and ethanol-induced 
ataxia in rodents (Taslim et al. 2008). In addition, balance deficits in rats following traumatic 
brain injury are ameliorated by the administration of the cholinesterase inhibitor physostigmine, 
which increases extracellular levels of acetylcholine, thereby activating nicotinic receptors 
(Holschneider et al., 2011). 
Clinical studies have shown that the nicotinic agonist varenicline improves gait and/or 
balance deficits in patients with spinocerebellar ataxia type 3 (SCA3) and type 14 (SCA14) 
(Zesiewicz and Sullivan, 2008), and a recent double-blind, placebo-controlled, randomized 
study demonstrated that treatment with varenicline for 2 months improved axial symptoms and 
rapid alternating movements in adult patients with genetically confirmed SCA3 (Zesiewicz et al., 
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2012). Preclinical studies from our laboratory have shown that varenicline attenuates balance 
deficits on the rotorod and balance beam in animals with olivocerebellar lesions (Wecker et al., 
2013), but the effects of varenicline on lesion-induced gait deficits in laboratory animals have 
not been investigated. 
Assessments of gait abnormalities in both ataxic laboratory animals and humans is 
typically confounded by inherent variability within a given population, as well as walking speed 
during the assessment (Cendelin et al., 2010; Wuehr et al., 2013). The variability confound has 
been addressed in the clinical literature by the use of principal component analysis (PCA) and 
the subsequent determination of a gait index to express gait deviations from a normal 
population (Schutte et al., 2000; Wren et al., 2007; Schwartz an drozumalski, 2008; Gouelle et 
al., 2013). A similar approach has been used in our laboratory for preclinical studies in rats 
following the administration of the neurotoxin 3-acetylpyridine (3-AP), which destroys the 
olivocerebellar pathway (Lambert et al., 2014). These studies demonstrated that ataxic animals 
exhibited a nearly 3-fold increase in deviation from normal gait compared to age-matched non-
lesioned animals. This finding, in concert with alterations in specific gait variables in ataxic rats 
that parallel those reported in clinical studies, suggested that this approach may be translatable 
and used to investigate the potential therapeutic benefits of nicotinic receptor agonists for the 
treatment of ataxia. Thus, the goals of this study were to: (1) use a PCA to isolate the key 
components of gait in animals walking on a motorized treadmill; (2) calculate a cumulative gait 
index (CGI) as a general measure of gait function relative to population norms; and (3) evaluate 
the dose–response effects of varenicline on 3-AP-induced gait impairments in laboratory rats 
following olivocerebellar lesions. 
 
3.3. Materials and Methods 
3.3.1. Animals 
Adult male Sprague–Dawley rats (225–250 g and 59–66 days old; n = 63; Harlan 
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Industries, Indianapolis, IN) were housed two per cage (with enrichment) in a temperature and 
humidity-controlled vivarium on a 12:12 h light-dark cycle (6 am:6 pm) with food and water 
available ad libitum. Animals were acclimated for 1 week prior to study and all behavioral 
evaluations were conducted between 10 am and 2 pm. The care and use of animals were 
approved in accordance with guidelines set by the University of South Florida Institutional 
Animal Care and Use Committee and the National Institutes of Health Guide for the Care and 
Use of Laboratory Animals. 
 
3.3.2. Apparatus 
The DigiGait™ Imaging System and software (version 12.2; Mouse Specifics, Boston, 
MA) were used to generate temporal and spatial gait parameters as described (Lambert et al., 
2014). Gait parameters, analyzed by a rater blinded to experimental condition, were generated 
from the hind limbs and included both temporal (swing duration, braking duration, propulsion 
duration, stance duration, stride duration and stride frequency) and spatial (stride length, stance 
width, paw angle, step angle, and paw area) measures, all of which are affected by the 
administration of 3-AP (Lambert et al., 2014). 
 
3.3.3. Training and baseline determinations 
Animals were trained to walk on the treadmill at speeds of 25 and 35 cm/s for 2 min at 
each speed for 5 consecutive days, with the 35 cm/s trial run 1.5 h after the 25 cm/s trial. The 
treadmill belt and enclosure were wiped with 70% ethanol between trials. At 2–3 days following 
completion of training, baseline performance was assessed for 2 min at each speed, and gait 
parameters were generated from a sequence consisting of at least 3 uninterrupted strides per 
paw, i.e., a total of 6 strides (Lambert et al., 2014). Animals that did not perform this sequence 
on a given trial were retested once at that speed. Of the 63 animals tested at baseline, 4 failed 
to meet this criterion and were removed from further study. For each animal, the number of 
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sequences generated within the 2 min trial at each speed was quantified, similar to a prior study 
(Lambert et al., 2014). 
A PCA was performed using the gait measures collected at baseline (n = 59) using both 
treadmill speeds. The factor loadings generated from this analysis were used to weight z-
transformed gait variable data, which were then summed to produce deviation values for each 
identified factor. These values were summed to yield the CGI, an index representing overall 
deviations from prototypical gait patterns (Lambert et al., 2014). CGI values were calculated for 
each animal at each assessment time, and the group means determined. 
 
3.3.4. Lesion induction and varenicline treatment 
Following baseline gait assessments, animals were randomly assigned to either non-
lesioned (n = 11) or lesioned (n = 48) groups (Fig. 3.1) The non-lesioned group was included to 
ascertain whether multiple exposures to the apparatus over time affected gait. The non-lesioned 
animals were handled in a manner identical to the lesioned animals, but did not receive any 
injections. Animals in the lesioned group received intraperitoneal (i.p.) injections of 3-AP (70 
mg/kg, Sigma–Aldrich Co., St. Louis, MO) followed by nicotinamide (300 mg/kg, i.p.) 3.5 h later 
to selectively destroy the olivocerebellar pathway (Wecker et al., 2013; Lambert et al., 2014). At 
1 week following baseline characterization, animals were reassessed on the treadmill for 2 min 
at 25 and 35 cm/s. Of the 48 animals who received 3-AP, 3 would not perform on the treadmill; 
thus, the remaining 45 animals were randomly assigned to 1 of 4 groups and received daily 
subcutaneous (s.c.) injections of either normal phosphate-buffered saline (PBS; 0.9%; 0.33 
ml/kg) or varenicline tartrate (0.3, 1.0 or 3.0 mg free base/kg corresponding to 0.51, 1.71, and 
5.13 mg tartrate salt/kg, respectively, from Tocris Bioscience, Bristol, UK or 0.43, 1.43, and 4.29 
mg dihydrochloride salt/kg, respectively, kindly provided by Dr. F. Ivy Carroll, Research Triangle 
Institute, Research Triangle Park, N.C.) for 2 weeks. The doses of varenicline were selected 
based on studies demonstrating improvement of the performance of olivocerebellar-lesioned 
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animals on the rotorod and balance beam, while the treatment duration was selected based on 
evidence that improvement on the rotorod plateaued following daily administration of varenicline 
for 2 weeks (Wecker et al., 2013). Stock solutions of varenicline were prepared weekly by 
dissolving the drug in PBS, and adjusting the pH to 7.4 with 1.0 N NaOH; aliquots were 
prepared, protected from light and stored at 4oC until use. 
 
3.3.5. Gait assessment and statistics 
As indicated, gait was reassessed for 2 min at each speed for all animals at 1, 2, and 3 
weeks after baseline testing, and animals in the non-lesioned group were evaluated in parallel 
with lesioned animals (Fig. 3.1). Gait measures across assessment times were compared using 
analysis of variance (ANOVA) with speed and time as repeated measures, and a subsequent 
repeated measures ANOVA at each speed was used to isolate simple effects; planned 
comparisons to detect differences between assessments were conducted using Fisher’s least 
significant difference (LSD) test. Data were analyzed for violations of sphericity, and in those 
instances indicating significant violations, a Geisser–Greenhouse correction was utilized to 
adjust criteria for significance. 
For lesioned animals, behavior was always assessed prior to the daily administration of 
varenicline to ensure that the acute locomotor effects of the drug did not influence performance 
on the treadmill. Because 4 of the 45 lesioned animals were unable to complete an 
uninterrupted 6 stride sequence at 25 cm/s, gait parameters for these animals, irrespective of 
treatment group, were generated from a minimum 3 stride sequence. This approach was 
validated by our prior study demonstrating that gait parameters generated from the truncated 
sequence did not differ significantly from those generated from a longer sequence (Lambert et 
al., 2014). 
A second PCA (termed iPCA) was performed using data generated 1 week post 3-AP to 
identify the principal components of impaired gait in the lesioned population. This analysis was 
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used to calculate the iCGI, an index reflecting gait deviations within the impaired population, and 
used to ascertain whether varenicline affected prototypical impaired gait. The iCGI values were 
calculated at 1 week following the administration of 3-AP, and following the administration of 
saline or varenicline. To control for differences in the degree of impairment in each animal, 
values from saline- or varenicline-injected animals were expressed relative to their 1 week 
values. Data were compared using a 2 × 4 repeated-measures ANOVA (assessment × 
treatment condition) with subsequent planned comparisons using Fisher’s LSD test to determine 
if varenicline administration altered the gait of lesioned animals. A p-value <0.05 was accepted 
as criterion for statistical significance for all analyses. 
 
3.4. Results 
3.4.1. Gait in non-lesioned animals 
Non-lesioned animals completed 11 ± 2.1 and 18 ± 2.9 sequences consisting of 6–11 
strides during the 25 and 35 cm/s baseline assessments, respectively, and the number of 
sequences did not change across weeks. Analysis of gait indicated that several temporal and 
spatial measures differed significantly (p < 0.05) from baseline at a treadmill speed of 25 cm/s 
(Fig. 3.2). Stride, stance, propulsion and swing durations increased 12–17% and stride length 
increased 12–14% over time, with a plateau apparent at 2 weeks [for stride duration, F(3,28) = 
9.84; for stance duration, F(3,28) = 7.70; for propulsion duration, F(3,28) = 9.11; for swing 
duration, F(3,28) = 7.69; for stride length, F(3,28) = 9.33]. Stance width and step angle 
decreased over time, with significant (p < 0.05) effects only at 3 weeks [for stance width, F(3,28) 
= 3.68; for step angle, F(3,28) = 4.12]; no other gait parameters exhibited time-dependent 
alterations. At a treadmill speed of 35 cm/s, all gait parameters exhibited changes similar to, but 
less than those observed at 25 cm/s (data not shown). 
A PCA was conducted using baseline gait measures from all animals at both treadmill 
speeds to reduce the dimensions of the dataset. This analysis identified four principal 
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components that accounted for 82% of the variance in the data (Table 3.1). The first factor or 
Rhythm [eigenvalue (e) = 4.9] included the temporal parameters stride duration, stride 
frequency, stance duration, and propulsion duration as primary measures (absolute loading 
value >0.5), while the second factor or Thrust (e = 2.1) included braking duration, stride length, 
stance width, and step angle as primary measures. Although the absolute loading value for paw 
angle was >0.5 for the Thrust component, the magnitude of this measure was greater for the 
third factor or Contact (e = 1.14), which also included paw area, identical to prior observations 
(Lambert et al., 2014). However, unlike prior observations, the PCA identified a fourth 
component, termed Gain (e = 1.1), that contained the single measure of swing duration; 
although step angle had a loading value >0.5 for Gain, the magnitude of this measure was 
greater for Thrust. Additional analyses performed using the 1, 2 and 3 week gait measures from 
non-lesioned animals indicated that the factors identified at baseline were unaffected by 
repeated treadmill exposure. Therefore, these factors were used to calculate a CGI for non-
lesioned animals at each assessment time, reflecting alterations at both treadmill speeds. In 
agreement with a prior study (Lambert et al., 2014), the CGI did not differ significantly between 
baseline and assessment week 1 (Fig. 3.2). However, at 2 and 3 weeks, the CGI increased 
significantly [F(3,28) = 4.91, p < 0.05] by 74% and 61%, respectively, indicating an increased 
deviation from baseline within the non-lesioned population. Further, analysis of each principal 
component indicated that this divergence within the population could be attributed to a greater 
than 2-fold increase in Rhythm [F(3,28) = 4.77, p < 0.05]. Although Thrust and Contact 
increased by 35–57%, and contributed to the overall increase in the CGI, these increases were 
not significant; Gain did not change over time. 
 
3.4.2. Gait in lesioned animals 
The effects of olivocerebellar lesions on gait parameters were assessed in rats at weekly 
intervals at 1 week after the administration of 3-AP and following injections of saline for 2 
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weeks. One lesioned animal failed to run on the treadmill at 2 and 3 weeks, and thus, was 
removed from study. The number of 6–11 stride sequences decreased at 1 week following 3-AP 
administration and remained stable thereafter. At 25 cm/s, the number of sequences at 
baseline, 1, 2, and 3 weeks after 3-AP administration was 12 ± 1.1, 7.0 ± 0.94, 6.3 ± 0.8, and 
7.0 ± 1.1, respectively. At 35 cm/s, the number of sequences at baseline, 1, 2, and 3 weeks 
after 3-AP administration was 18 ± 1.4, 8.8 ± 1.1, 11 ± 1.5, and 11 ± 2.1, respectively. 
Gait parameters that differed significantly (p < 0.05) over time at a treadmill speed of 25 
cm/s are shown in Fig. 3.3. At 1 week after the administration of 3-AP, stride, stance and 
propulsion durations decreased significantly (p < 0.05) by 10%, 14%, and 19%, respectively [for 
stride duration, F(3,27) = 5.39; for stance duration, F(3,27) = 8.41; for propulsion duration, 
F(3,27) = 7.40]. These temporal parameters exhibited recovery over time with stride duration at 
3 weeks not significantly different from baseline; stance and propulsion durations at this time 
were still significantly less (p < 0.05) than baseline. Several spatial parameters were also 
significantly (p < 0.05) affected at 1 week following the administration of 3-AP with a 10% 
shorter stride length, a 42% larger stance width, a 34% smaller paw area, and a 3.6-fold 
increase in paw angle [for stride length, F(3,27) = 5.03; for stance width, F(3,27) = 9.15; for paw 
area, F(3,27) = 20.2; for paw angle, F(3,27) = 33.3]. By 3 weeks, stride length recovered and 
values were not significantly different from baseline. Although paw area exhibited some 
recovery, values at 2 and 3 weeks were significantly (p < 0.05) different from those at both 
baseline and 1 week following the administration of 3-AP. In contrast, neither stance width nor 
paw angle exhibited recovery, with values at 2 and 3 weeks that remained significantly (p < 
0.05) different from baseline. At a treadmill speed of 35 cm/s, all gait parameters exhibited 
changes similar to those at 25 cm/s, albeit the magnitude was less, similar to observations from 
non-lesioned animals (data not shown). 
Lesion-induced alterations in gait parameters at both treadmill speeds are reflected in 
the CGI, shown in the lower right corner of Fig. 3.3. The lesion resulted in a significant (p < 
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0.05) 2.9-fold increase in the CGI at 1 week [F(3,27) = 21.1], and this increase persisted for the 
following 2 weeks. Analysis of each principal component (Fig. 3.4) indicated that this increase 
was attributed to significant (p < 0.05) increases in both Thrust [F(3,27) = 16.3] and Contact 
[F(3,27) = 23.7]. Also depicted in the stacked histogram is a comparison of principal 
components in lesioned versus non-lesioned groups, further illustrating that the increased CGI 
following the lesion differed from that in non-lesioned rats, which was attributed to increased 
Rhythm. 
This finding, in concert with results indicating that gait changes in lesioned animals 
persisted over time, led to a second analysis to determine the principal components of gait in 
impaired animals, termed the iPCA. This analysis identified factors that accounted for 86% of 
the total variance in the data (Table 3.2) and indicated that for lesioned animals, iRhythm (e = 
4.9) included all the temporal parameters identified in non-lesioned animals with the addition of 
swing duration; although paw area had a loading value >0.5 for iRhythm, the magnitude of this 
measure was greater for iContact. iThrust (e = 1.9) included those measures identified in non-
lesioned animals with the exception of stance width; the loading value for step angle was larger 
for iContact. iContact (e = 1.56) was composed of paw angle and area, which were identified in 
the non-lesioned population as part of this factor, but also included both stance width and step 
angle. Although iGain (e = 1.04) reflected stride length, which was not identified as part of this 
factor in the non-lesioned population, the loading value for this measure was greater for iThrust. 
Thus, the principal components of gait in the lesioned population reflected slightly different 
relationships and loading factors for gait measures than in the non-lesioned population. The 
iPCA was used to calculate the iCGI to evaluate the effects of varenicline on gait in lesioned 
animals. Two animals had iCGI values that were greater than 2 standard deviations from the 
mean and thus were excluded, resulting in a mean iCGI for all lesioned animals at 1 week 
following 3-AP administration of 6.91 ± 0.40 (n = 43). 
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3.4.3. Effects of varenicline on gait in lesioned animals 
The effects of varenicline on the iCGI, expressed relative to values determined 1 week 
after the administration of 3-AP, are shown in Fig. 3.5 and illustrate that the daily administration 
of 3.0 mg/kg varenicline increased the iCGI, an effect that was significant [F(3,37) = 2.98, p < 
0.05] relative to all other groups following 2 weeks of drug administration (3 week assessment). 
Further, at 2 and 3 week assessments, the proportion of animals with increased iCGIs, denoting 
a greater deviation from the impaired state, was greater for all varenicline-injected groups than 
for the saline group. For the saline group, 50% of the animals (5/10) exhibited a (+) and 50% 
exhibited a (−) iCGI change at 2 and 3 weeks following the lesion, whereas in all varenicline-
injected groups, greater than 50% (60–90%) of the animals exhibited a (+) change indicating a 
tendency to change from impaired performance. 
Analysis of the factors comprising the iCGI indicated that the increased deviation from 
impaired gait following varenicline (3.0 mg free base/kg) treatment (Table 3.3) was attributed to 
a significant (p < 0.05) 3-fold increase in iRhythm [F(3,37) = 3.61] and an almost 2-fold increase 
in iThrust relative to saline-injected group values. Although the overall ANOVA for the latter was 
not significant [F(3,37) = 1.62], a planned comparison of saline versus varenicline (3.0 mg free 
base/kg) indicated a significant (p < 0.05) difference between groups. As a consequence of 
these findings, individual gait parameters from non-lesioned and lesioned animals following the 
administration of saline or varenicline (3.0 mg free base/kg) for 2 weeks were compared at 3 
weeks. Results are shown in Fig. 3.6. The administration of varenicline normalized swing 
duration, i.e., swing duration for varenicline-injected animals was significantly (p < 0.05) different 
than for saline-injected animals, and not significantly different from the non-lesioned group 
[F(2,29) = 6.50]. In addition, saline-injected animals exhibited significant (p < 0.05) alterations in 
stride duration, stride length, and step angle relative to non-lesioned animals, whereas these 
gait parameters did not differ between varenicline-injected and non-lesioned animals [for stride 
duration, F(2,29) = 5.79; for stride length, F(2,29) = 5.44; for step angle, F(2,29) = 5.45].  
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Thus, varenicline ‘tended to normalize’ stride duration, stride length, and step angle.  
 
3.5. Discussion 
The goal of this study was to determine the dose–response effects of varenicline on 3-
AP-induced gait impairments in laboratory rats following olivocerebellar lesions using a PCA 
and consequent calculation of a single index to characterize gait deviations. Results 
demonstrate that the gait of ataxic animals differs from that of non-lesioned animals, and that 
the administration of 3.0 mg free base varenicline for 2 weeks leads to gait adaptations of 
several parameters. Importantly, these adaptations attenuate 3-AP-induced gait impairments at 
a walking speed of 25 cm/s, suggesting that these animals compensate for their impairment by 
altering several components of gait. 
The present study extends prior findings (Lambert et al., 2014) and demonstrates that 
weekly experience on a treadmill for up to 3 weeks, albeit limited to 4 min per time, leads 
animals to acclimate or habituate to the apparatus, resulting in a significant increased deviation 
of gait relative to baseline determinations. Analysis of the factors that comprised the CGI 
revealed that the maximal 74% increased deviation over time could be attributed primarily to 
alterations in Rhythm, which reflected changes in the temporal measures of stride, stance, and 
propulsion durations. Thus, increased treadmill experience leads to alterations in gait cadence 
in normal animals over time. 
In contrast to the role of temporal measures (Rhythm) underlying the increased CGI in 
non-lesioned animals over time, analysis of the factors contributing to the increased CGI as a 
consequence of the lesion indicated a role for Thrust and Contact, reflecting primarily stride 
length, stance width, step angle, and paw area and angle. Thus, the primary deficit in lesioned 
animals may be attributed to spatial alterations, and are likely responsible for the inability of 
these animals to maintain the temporal parameters involved in normal rhythm. Due to the major 
differences in gait between lesioned and non-lesioned animals, a second PCA was performed 
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on lesioned animals to identify components of the principal factors in the impaired population, 
and thus serve as a reference for evaluating the effects of varenicline. 
Results from the iPCA determined from gait measures in lesioned animals were similar, 
but not identical to those from the PCA determined from baseline gait measures from non-
lesioned animals. The major difference between these analyses was a change in the 
association of swing duration from Gain for the PCA to iRhythm for the iPCA. In addition, stance 
width and step angle, which were associated only with Thrust for the PCA, were associated with 
both iThrust and iContact for the iPCA, with the loadings for iContact greater than those for 
iThrust. Thus, following 3-AP administration, the timing of the gait cycle (iRhythm) is limited by 
the duration of the swing phase, and the contribution of stance width and step angle to Thrust is 
reduced. Importantly, the large increase in association of stance width with iContact likely 
indicates a postural change to increase the base of support of the animal. Because step angle is 
directly influenced by stance width, the increased association of step angle with iContact is most 
likely due to this change in stance width. Thus, the iPCA identified a new basis that best 
represents the dynamics of gait in the lesioned population relative to the non-lesioned 
population, and as such, represents a valid reference for evaluating the effects of varenicline. 
When the iCGI was calculated from the iPCA and the dose–response effects of varenicline 
determined, results indicated that the highest dose of drug (3.0 mg free base/kg) administered 
for 2 weeks led to a nearly 2-fold increase in the iCGI, indicating that gait following the 
administration of this dose of varenicline was unlike that of the impaired population. Further, this 
increase was attributed to increases in iRhythm and iThrust. Analysis of individual gait 
parameters indicated that the increase in iRhythm reflected a drug-induced increase in swing 
duration and consequent increased stride duration to values that did not differ from the non-
lesioned population. Similarly, the increase in iThrust reflected an increase in stride length and 
consequent decrease in step angle to values that were not significantly different from those in 
the non-lesioned population. Thus, varenicline enabled animals to compensate for their 
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impairment by normalizing swing duration and stride length, thereby rectifying the timing of the 
gait cycle. 
Although several studies have used a treadmill system to investigate alterations in both 
temporal and spatial gait parameters in animal models of disease (Berryman et al., 2009; Piesla 
eta l., 2009; Song et al., 2012; Hansen and Pulst, 2013; Jiang et al., 2015), it can be difficult to 
conceptualize how alterations in the parameters generated affect overall gait, especially 
because of differences in magnitude and direction. Using a PCA to identify the key components 
of gait enables calculation of an index representing gait deviations from a defined population. 
Although this method has been used clinically to characterize gait deficits in several clinical 
conditions (Schutte et al., 2000; Wren et al., 2007; Schwartz and Rozumalski, 2008; Gouelle et 
al., 2013), it has not been adopted for use in preclinical studies. This approach has tremendous 
power in that it provides a single value from a large and often redundant dataset that is sensitive 
to small changes in individual gait measures, and should be utilized because of its translational 
potential to provide a succinct and reliable indicator of gait deviation. 
Results from this preclinical study, as well as clinical evidence (Zesiewicz et al., 2012), 
clearly indicate that varenicline is efficacious for alleviating both balance and gait deficits in 
ataxia. It remains to be determined whether these actions: (1) are mediated by the varenicline-
induced activation or desensitization of neuronal nicotinic receptors, and which specific receptor 
subtypes are involved; and (2) occur as a consequence of a direct effect on the cerebellum or 
other anatomic regions. Indeed, varenicline has been shown to have full and/or partial agonist 
activity at α4β2, α3β2, α3β4, α6-containing, and homomeric α7 nicotinic receptors (Mihalak et al., 
2006; Rollema et al., 2007a; Rollema et al., 2007b; Chatterjee et al,. 2011), all of which are 
expressed in the cerebellum (Turner and Kellar, 2005; Turner et al., 2011; Caruncho et al., 
1997). Alternatively, it is possible that the direct effects of varenicline are mediated by other 
neuroanatomical regions. This idea is supported by studies indicating that the loss of balance 
resulting from cortical impact injury leads to compensatory changes in brain regions remote to 
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the site of injury, and that administration of the cholinesterase inhibitor physostigmine, which 
alleviated the impairment, increased the activity of these remote pathways (Holschneider et al., 
2013). 
In sum, results indicate that varenicline improves gait in laboratory animals with 
olivocerebellar lesions, a finding similar to that reported for patients with SCA3 (Zesiewicz et al., 
2012); the cellular mechanisms involved remain to be elucidated. Results also underscore the 
benefit of using a PCA to consolidate specific gait measures into a limited number of factors to 
characterize gait. This analysis can then be used to provide a meaningful index that is sensitive 
to subtle changes in gait function. This approach represents a powerful tool that has been 
underutilized in both preclinical and clinical studies. 
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3.8. Figures and Tables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.1. Experimental paradigm. Rats were trained to walk on the DigiGait™ system for 5 
consecutive days and gait assessments were conducted at baseline and weekly thereafter for 
up to 3 weeks. Non-lesioned (control) animals were assessed in parallel with lesioned animals, 
the latter receiving injections of 3-AP following baseline assessment. At 1 week after the lesion 
and reassessment, rats received daily injections of either saline or varenicline (0.3, 1.0, or 3 mg 
free base/kg); gait was reassessed following 1 or 2 weeks. A PCA was conducted using gait 
data generated from all animals at baseline, and results used to calculate a CGI for non-
lesioned and lesioned/saline-injected rats. Similarly, an analysis was also performed with gait 
data from all lesioned animals (iPCA), and results used to calculate the iCGI for lesioned/saline-
injected and lesioned/varenicline-injected rats. The CGI or iCGI were calculated using z-
transformations of each gait measure and the loadings from the PCA or iPCA, respectively. 
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Fig. 3.2. Gait parameters and the CGI in control rats. Temporal and spatial gait parameters 
were determined in rats for 2 min at treadmill speeds of 25 and 35 cm/s at weekly intervals; 
data shown is from 25 cm/s. Each point is the mean ± S.E.M. of determinations from 11 
animals. Data were analyzed by a one-way ANOVA and Fisher’s LSD test. The asterisks 
denote significant (p < 0.05) differences from baseline (Base). 
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Fig. 3.3. Gait parameters and the CGI in lesioned rats. Temporal and spatial gait parameters 
were determined in rats for 2 min at treadmill speeds of 25 and 35 cm/s at baseline (Base) and 
weekly intervals following the administration of 3-AP; data shown is from 25 cm/s. Each point is 
the mean ± S.E.M. of determinations from 10 animals. Data were analyzed by a one-way 
ANOVA and Fisher’s LSD test. The single asterisks denote significant (p < 0.05) differences 
from baseline; the double asterisks denote significant (p < 0.05) differences from 1 week 
determinations. 
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Fig. 3.4. Effects of 3-AP on CGI principal component deviations. Z-transformations of each gait 
measure and the loadings from the PCA were used to calculate the deviations attributed to each 
factor. Values for each factor from non-lesioned (NL) and lesioned (Les) animals were 
calculated following weekly assessments and compared using a 2 × 4 repeated-measures 
ANOVA (treatment × assessment) and Fisher’s LSD test. Data represent mean ± S.E.M. of 
determinations from 11 (NL) or 10 (Les) animals per group. The asterisks denote significant (p < 
0.05) differences from corresponding group baseline values. 
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Fig. 3.5. Effects of varenicline on the iCGI. Temporal and spatial gait parameters were 
determined in rats for 2 min at treadmill speeds of 25 and 35 cm/s following the administration of 
3-AP, and a PCA was conducted using gait data generated from all lesioned animals (iPCA), 
with results used to calculate the iCGI. Following the 1 week gait assessment, animals received 
daily injections of saline or varenicline (0.3, 1.0 or 3.0 mg free base/kg), and gait reassessed 
weekly for the following 2 weeks. The mean iCGI of all lesioned animals at 1 week following the 
administration of 3-AP was 6.91 ± 0.40 (n=43) and did not differ significantly by group 
assignment. The iCGI values at 2 and 3 weeks after 3-AP were: 7.2 ± 0.47 and 7.7 ± 1.3, 
respectively, for the saline group; 8.5 ± 1.4 and 8.0 ± 0.8, respectively, for the 0.3 mg/kg 
varenicline group; 8.2 ± 0.77 and 7.9 ± 1.1, respectively, for the 1.0 mg/kg varenicline group; 
and 8.8 ± 1.2 and 10.5 ± 1.2, respectively, for the 3.0 mg/kg varenicline group. Data are 
expressed relative to pretreatment (1 week assessment) values to control of individual 
differences in impairments. The bars represent group mean values ± S.E.M., and the ratio in 
each bar is the number of animals exhibiting a (+) change relative to initial lesioned values 
relative to the total number of animals (n) in each group. Data were analyzed by a 2 × 4 ANOVA 
(assessment × treatment) and Fisher’s LSD test. The asterisk denotes significant (p < 0.05) 
differences from saline group values. 
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Fig. 3.6. Effects of saline or varenicline on absolute gait measures. Temporal and spatial gait 
parameters were determined in lesioned rats following the daily administration of saline (Sal) or 
varenicline (Var, 3.0 mg free base/kg) for 2 weeks, and in corresponding non-lesioned (NL) rats. 
Bars represent the mean ± S.E.M. of determinations from 10 (Sal or Var) or 11 (NL) 
animals/group. Data were analyzed by ANOVA and Fisher’s LSD test. The single asterisk 
denotes significant (p < 0.05) differences from NL group values and the double asterisk denotes 
significant (p < 0.05) differences from Sal group values. 
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Table 3.1. Principal Component Analysis at Baseline. Note: A principal component analysis was 
conducted using gait measures from baseline assessments of all animals (n = 59). For each 
measure, the largest absolute loading value across the 4 factors is bolded, representing primary 
components of each factor. 
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Table 3.2. Principal Component Analysis in Impaired Animals (iPCA). Note: A principal 
component analysis was conducted using gait parameters generated from animals (n = 45) at 1 
week after the administration of 3-AP, termed the iPCA. For each variable, the largest absolute 
loading value across the 4 factors is bolded, representing primary components of each factor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
80 
 
 
Table 3.3. Effects of Varenicline on iCGI Principal Component Deviations. Note: Animals 
received 3-AP followed 1 week alter by daily injections of saline or varenicline for 2 weeks. The 
z-transformations of each gait measure and the loadings from the iPCA were used to calculate 
the deviations attributed to each factor. Values for each factor were calculated and compared 
using ANVOA, and Fisher’s LSD test was used for planned comparisons of saline versus 
varenicline. Data represent mean ± S.E.M. of determinations from 10 (saline and varenicline, 
1.0 and 3.0 mg/kg) or 11(varenicline, 0.3 mg/kg) animals per group. The asterisks denote 
significant (p < 0.05) differences from corresponding saline group values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
81 
 
 
 
 
Chapter Four: 
Mecamylamine can attenuate gait impairments in rats with olivocerebellar lesions to a 
similar extent as varenicline 
 
Note to reader: 
C.S. Lambert contributed to the execution and analysis of these studies as well as their 
preparation for publication. R.M. Philpot and L. Wecker contributed to the design, analysis, and 
preparation of this study for publication. 
 
C.S. Lambert, R.M. Philpot, L. Wecker 
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4.1. Abstract 
 Balance and gait dysfunction are common deficits manifest in patients with ataxic 
disorders, and treatment options are currently limited for these patients. Recent studies from our 
laboratory have demonstrated improvements in balance and gait in animals with olivocerebellar 
lesions following chronic administration of nicotinic receptor agonist varenicline. As the 
mechanism underlying this phenomenon is unknown, the objective of this study was to 
determine if varenicline’s effect could be blocked using the nicotinic antagonist mecamylamine. 
Male Sprague-Dawley rats were trained to walk on a motorized treadmill, and temporospatial 
gait parameters were obtained and subjected to a principal component analysis to identify 
primary gait components and produce a cumulative gait index (CGI) that characterized typical 
gait. Animals were then injected with 3-acetylpyridine followed by nicotinamide to lesion the 
olivocerebellar pathway and produce ataxia. Gait performance was investigated following 
induction of the lesion and one and two weeks following chronic administration of saline, 
varenicline, mecamylamine and varenicline, or mecamylamine alone. As a result of the lesion, 
animals exhibited a 2.4-fold increase in gait deviation. Following two weeks of chronic 
treatment, varenicline-injected animals exhibited attenuations of gait impairments. Furthermore, 
animals receiving mecamylamine injections exhibited attenuations of gait impairments in a 
similar manner as varenicline-injected animals, whereas when mecamylamine and varenicline 
were used in combination, only the low dose of mecamylamine blocked the effects of 
varenicline. Thus, evidence suggests that the mechanism underlying varenicline’s ability to 
attenuate gait impairments is mediated through nicotinic receptor inactivation. 
Keywords 
Ataxia, gait, principal component analysis, varenicline, mecamylamine 
Abbreviations 
CGI: Cumulative Gait Index; PCA: Principal Component Analysis 
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4.2. Introduction 
Evidence from preclinical studies demonstrates that modulation of cholinergic signaling 
can improve motor functioning in animals with motor dysfunction. For example, the 
administration of the cholinesterase inhibitor physostigmine can ameliorate balance deficits in 
rats as a result of traumatic brain injury (Holschneider et al., 2011) and nicotine can attenuate 
ethanol-induced ataxia on the rotorod in mice (Al-Rejaie and Dar, 2006; Dar et al., 1993). 
Studies from our laboratory have demonstrated that chronic administration of the nicotinic 
agonist varenicline to rats with ataxia attenuates balance deficits on a beam, and both nicotine 
and varenicline can improve performance on a rotorod (Wecker et al., 2013). Additionally, gait 
impairments as a result of olivocerebellar lesions in rats can be attenuated by chronic 
administration of nicotine when animals’ gait is assessed by a static gait analysis (Wecker et al., 
2013) as well as by chronic administration of varenicline when rats walk on a motorized 
treadmill (Lambert et al., 2015). Other studies have demonstrated the ability of chronic 
administration of nicotine, varenicline, and other nicotinic agonists to reduce L-DOPA-induced 
dyskinesias in several preclinical models of Parkinson’s disease (Bordia et al., 2010; Zhang et 
al., 2013; Quik et al., 2013; Zhang et al., 2014a; Zhang et al., 2014b).  
Importantly, the underlying mechanism by which nicotinic agonists may improve 
balance, gait, or motor dysfunction is presently unknown. Results from a prior study 
demonstrate the effects of chronic nicotine administration to attenuate an impairment in stance 
width could be blocked by the nonspecific nicotinic antagonist mecamylamine, implicating 
nicotinic receptor activation as the mechanism (Wecker et al., 2013). However, it has also been 
shown that chronic administration of nicotinic antagonists such as mecamylamine can similarly 
improve motor deficits. For example, chronic administration of mecamylamine can reduce the 
severity of motor tics in patients with Tourette’s syndrome (Silver et al., 2000) and can reduce L-
DOPA-induced dyskinesias to a similar extent as nicotine in rats with 6-hydroxydopaminergic 
lesions (Bordia et al., 2010). Notably, the results of the latter study suggest that both nicotine 
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and mecamylamine attenuate L-DOPA-induced dyskinesias through a similar mechanism 
(Bordia et al., 2010). 
The mechanism by which both nicotinic agonists and antagonists can improve motor 
dysfunction is unclear. Furthermore, varenicline’s mechanism of action to attenuate gait 
impairments in rats with ataxia is also unknown, and thus, the goal of this study was to further 
elucidate the mechanism by varenicline can improve motor function by using the nicotinic 
antagonist mecamylamine. It was investigated whether mecamylamine could block varenicline’s 
effects, thereby suggesting that this phenomenon is medicated through nicotinic receptor 
activation.  
 
4.3. Materials and Methods 
4.3.1. Animals 
 Adult male Sprague-Dawley rats (225-250g and 52-59 days old; n =85; Harlan 
Industries, Indianapolis, IN) were housed two per cage (with enrichment) in a temperature and 
humidity-controlled vivarium on a 12:12 hour light-dark cycle (6 AM: 6 PM). Food and water 
were available ad libitum and animals were acclimated to the vivarium for 1 week prior to the 
onset of the study. All behavioral assessments were conducted between 10 AM-2 PM. The care 
and use of animals were approved in accordance with guidelines set by the University of South 
Florida Institutional Animal Care and Use Committee and the National Institutes of Health Guide 
for the Care and Use of Laboratory Animals. 
 
4.3.2. Apparatus 
 The DigiGait™ Imaging System and software (version 12.5; Mouse Specifics, Boston, 
MA) were used to assess the gait of animals throughout the experiment. Gait parameter values 
were generated from animal’s hindlimbs and included the temporal and spatial gait measures 
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affected by 3-AP (Lambert et al., 2014) that were investigated in a prior study (Lambert et al., 
2015).  
 
4.3.3. Animal Training and Baseline Assessment 
 Animals were trained to walk on the treadmill at 25 and 35 cm/s for two minutes at each 
speed for five consecutive days, and each animal walked at the faster speed 1.5 hours following 
the trial at the slower speed. The treadmill belt and enclosure were cleaned with 70% ethanol 
between each trial. Three days following completion of training, animals’ baseline performance 
was assessed for 2 minutes at both speeds, and hindpaw gait parameters were generated from 
a representative successful trial, which consisted of at least 3 uninterrupted strides per paw for 
a total of 6 strides (Lambert et al., 2014; 2015). A representative sequence generated from each 
animal within a 2-minute trial that met this criterion was used to generate temporospatial gait 
measures, similar to prior studies (Lambert et al., 2014; 2015). Animals that did not successfully 
generate a sequence that met criterion at either speed were reassessed once at that speed. Of 
the 85 animals tested, 8 failed to meet this criterion and were removed from further study. 
  
4.3.4. Lesion induction and drug treatment 
 One day following baseline assessment, animals were given intraperitoneal (i.p.) 
injections of 3-AP (70 mg/kg, Sigma-Aldrich Co., St. Louis, MO) and nicotinamide (300 mg/kg, 
i.p.) 3.5 hours later to selectively lesion the olivocerebellar pathway (Wecker et al., 2013). 
Animals’ performance was reassessed on the treadmill one week later to quantify gait 
impairments manifest as a result of the lesion. Of the 77 animals that received 3-AP, 9 did not 
walk on the treadmill one week following 3-AP administration and were removed from further 
study.  
The remaining 68 animals were randomly assigned to one of six treatment groups and 
received two daily subcutaneous (s.c.) injections for a total of two weeks of either: phosphate-
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buffered saline (PBS; 0.9%; 0.33 ml/kg) (n=15); PBS followed by 3 mg free base/kg varenicline 
(n=17); 0.8 mg free base/kg mecamylamine followed by either saline (n=9) or 3 mg free base/kg 
varenicline (n=10); or 3.2 mg free base/kg mecamylamine followed by either saline (n=8) or 3 
mg free base/kg varenicline (n=9). Injections for each animal were always separated by 30 
minutes, regardless of treatment assignment. For all animals, behavior was always assessed 
prior to daily injections to ensure that the acute locomotor effects of the drug did not influence 
treadmill performance. Gait was reassessed for all eligible animals 2 and 3 weeks following 
baseline assessment, or 6 and 13 days following induction of saline or drug treatment (Fig. 4.1). 
The dose of 3 mg free base/kg of varenicline tartrate (corresponding to 5.13 mg tartrate 
salt/kg from Tocris Bioscience, Bristol, UK) was selected based on prior findings that only this 
dose led to significant attenuations of 3-AP-induced gait impairments (Lambert et al., 2015). 
Mecamylamine used was mecamylamine hydrochloride (corresponding to 0.97 or 3.9 mg 
hydrochloride salt/kg, respectively, from Sigma-Aldrich Co., St. Louis, MO). The low dose of 0.8 
mg free base/kg mecamylamine and the time-course were selected based on a prior study from 
our laboratory demonstrating that a 30-minute pretreatment with 0.82 mg free base/kg 
mecamylamine blocked nicotine’s effects to attenuate gait impairments (Wecker et al., 2013). 
Additionally, the higher dose of 3.2 mg free base/kg mecamylamine was used to investigate 
dose-related effects at a dose that has been shown to block varenicline’s effects to enhance 
electrical brain-stimulation reward (Spiller et al., 2009). Stock solutions of the drugs were 
prepared weekly by dissolving the drug in PBS and adjusting the pH to 7.4 with 1.0N NaOH; 
aliquots were prepared, protected from light, and stored at 4oC until use.  
 
4.3.5. Assessment of gait, calculation of PCA, and statistics  
Although animals were assessed at two treadmill speeds (25 & 35 cm/s), only gait 
parameters obtained from the slower treadmill speed were used for analysis. This was due to 
prior findings that there were no significant attenuations of gait impairments when animals 
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walked at the faster speed of 35 cm/s (Lambert et al., 2015). A PCA was performed using the 
gait parameters collected from animals at baseline (n = 77) using data from 25 cm/s only. The 
factor loadings obtained from this analysis were used to weight z-transformed data for each gait 
parameter, and these values were summed to yield the CGI, a cumulative gait index that 
represented deviations from normal gait (Lambert et al., 2014; 2015). CGI values were 
determined for each animal at each assessment as described (Lambert et al., 2015), and the 
group means were calculated for each timepoint. CGI values across assessment timepoints 
were analyzed by a repeated-measures ANOVA and Fisher’s least significant difference (LSD) 
test. 
At the gait assessments 1 week following the administration of 3-AP and afterwards, gait 
parameters were generated from a representative walking sequence consisting of a minimum of 
3 total uninterrupted strides as several animals were unable to complete a total of 6 strides due 
to their impairment. Four and six animals did not walk sufficiently for gait analysis on the 
treadmill at the 2 and 3 week assessment timepoints, respectively, and were excluded from the 
remainder of the study. Gait measures across assessment timepoints were compared using 
analysis of variance (ANOVA) with time as a repeated measure. Planned comparisons were 
used to detect differences between assessment timepoints using Fisher’s LSD. Data were 
analyzed for violations of sphericity, and a Geisser-Greenhouse correction was used to adjust 
criteria for significance when significant violations occurred. 
Absolute gait measures for each gait parameter at the 3 week timepoint were compared 
using a 2 x 3 MANOVA [(+/- varenicline) x (no mecamylamine, low dose, or high dose 
mecamylamine)] to determine whether any dose or combination of the drugs attenuated 3-AP-
induced gait impairments. Subsequent planned comparisons between each treatment group 
and saline-injected animals were conducted using Fisher’s LSD post-hoc. A p-value of < 0.05 
was accepted as criterion for statistical significance for all analyses. 
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4.4. Results 
4.4.1. Effects of olivocerebellar lesions on gait  
A PCA was conducted using gait data from all animals at baseline at a treadmill speed of 
25 cm/s. Results of this analysis were similar to prior findings (Lambert et al., 2015) and 
revealed three principal components that explained 80% of the variance within the data (Table 
4.1) and was comprised of the factors Rhythmicity (e = 5.61), Thrust (e = 1.72), and Contact (e 
= 1.47). The lesion resulted in a significant (p < 0.05) 2.4-fold increase in the CGI at the week 1 
assessment timepoint that persisted across the remainder of assessments [F (3, 33) = 9.07] 
(Fig. 4.2). This increase could be attributed to significant increases in both Rhythmicity [F (3, 33) 
= 5.68] and Thrust [F (3, 33) = 8.25], but not Contact. 
Gait impairments as a result of 3-AP administration were of similar magnitude to those 
described (Lambert et al., 2014; 2015), and included significant (p < 0.05) differences between 
the baseline and 1 week assessment for swing, propulsion, stance, and stride durations, as well 
as for stride length, paw angle, stance width, step angle, and paw area.  
 
4.4.2. Effects of saline or drug administration upon gait impairments  
At the final assessment timepoint and in agreement with prior findings (Lambert et al., 
2014), saline-injected animals exhibited recovery of some temporal and spatial gait 
impairments, as the absolute gait measures were not significantly different from baseline (data 
not shown). However, further analyses revealed that saline-injected animals did not recover to 
the same extent as animals in other treatment groups. Results of the overall MANOVA revealed 
that there were several significant interactions between the treatment conditions including: 
stance duration [F (2, 52) = 3.58], stride duration [F (2, 52) = 3.26], stride length [F (2, 52) = 
3.27], and step angle [F (2, 52) = 3.26].  The results of subsequent planned comparisons are 
shown in Fig. 4.3 and illustrate significant (p < 0.05) differences between saline-injected and 
varenicline-injected groups for stance and stride durations, as well as for stride length. Values 
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for swing duration from varenicline-injected animals approached, but did not meet the criterion 
for statistical significance (p = 0.08).  
Similarly, either dose of mecamylamine alone led to animals exhibiting a significantly (p 
< 0.05) greater recovery from impairments for stance and stride durations and stride length 
when compared to saline-injected animals. Regarding the combinations of drugs, only animals 
in the 3.2 mg free base/kg mecamylamine and varenicline group exhibited significant (p < 0.05) 
attenuations of 3-AP-induced gait impairments for stance and stride durations and stride length. 
Conversely, animals in the 0.8 mg free base/kg mecamylamine and varenicline group did not 
exhibit statistically significant attenuations (p > 0.05) when compared to saline-injected animals 
and thus did not exhibit a similar recovery. Thus, when used in combination, the low dose of 
mecamylamine blocked the effects of varenicline to attenuate gait impairments, while a 
relatively high dose of varenicline, mecamylamine alone, and a higher dose of mecamylamine 
combined with varenicline led to significant attenuations of several 3-AP-induced gait 
impairments when compared to saline-injected animals.  
 
4.5. Discussion 
 The goal of this study was to use the nicotinic antagonist mecamylamine to determine if 
the effect of varenicline to attenuate 3-AP-induced gait impairments was mediated by activation 
of nicotinic receptors. These results demonstrate that mecamylamine alone was equally as 
effective as varenicline in attenuating impairments in one spatial and two temporal gait 
parameters and resulted in normalization of the timing of the gait cycle. Notably, chronic 
mecamylamine at a low dose antagonized the effects of varenicline to attenuate gait 
impairments, whereas mecamylamine at a higher dose did not antagonize the effect of 
varenicline. Indeed, animals injected with the latter combination showed equivalent attenuations 
of gait impairments as animals that received injections of mecamylamine or varenicline alone.  
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In agreement with these findings, prior results from our laboratory using a static gait 
analysis demonstrated that a low dose of mecamylamine (at a comparable dose of 0.82 mg free 
base/kg) did not attenuate an impairment in the spatial gait parameter stance width (Wecker et 
al., 2013). Furthermore, a low dose of mecamylamine blocked nicotine’s effects to attenuate an 
impairment in stance width, implicating nicotinic receptor activation as the mechanism (Wecker 
et al., 2013). Results from this study, including the finding that a low dose of mecamylamine 
similarly blocked the effects of varenicline to attenuate an impairment in stride length, extend 
prior findings by suggesting that nicotinic receptor inactivation is the mechanism underlying 
varenicline’s effects to attenuate gait impairments.  
Mecamylamine has been shown to dose-dependently block varenicline’s effects to 
enhance brain-stimulated reward mediated through receptor activation (Spiller et al., 2009).  
Thus, if receptor activation was the underlying mechanism for varenicline’s effects to attenuate 
gait impairments, it would be expected that this effect would be dose-dependently antagonized 
by mecamylamine. Furthermore, the effects of mecamylamine and varenicline in combination 
were not synergistic, suggesting that their effects to attenuate gait impairments when 
administered individually are mediated through a similar mechanism. In agreement with these 
results, both mecamylamine and nicotine have been documented to ameliorate L-DOPA-
induced dyskinesias in 6-hydroxydopamine-lesioned rats, but combining the drugs did not result 
in synergistic effects (Bordia et al., 2010).  
Studies have documented that chronic administration of both nicotine and 
mecamylamine increases nicotinic receptor expression within the plasma membrane (i.e. 
upregulation) (Marks et al., 1992; Perry et al., 1999; Collins et al., 1994; Pauly et al., 1996). 
Thus, it is plausible that the similar mechanism shared by nicotine and mecamylamine underlies 
nicotinic receptor upregulation following chronic administration of these drugs. Although 
receptor upregulation was not investigated in this study, this interpretation is supported by 
findings that chronic administration of varenicline similarly upregulates nicotinic receptors in the 
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brains of rodents (Hussmann et al., 2012; Marks et al., 2015). Increased expression of nicotinic 
receptors following chronic administration of nicotinic agonists has been shown to increase 
nicotinic receptor sensitivity as well as increase receptor desensitization in response to the 
binding of agonists (Henderson and Lester, 2015). Thus, upregulation of nicotinic receptors that 
are more easily desensitized may further explain the interpretation of Bordia et al., (2010) that 
the effects of nicotinic receptor agonists and antagonists to reduce L-DOPA-induced 
dyskinesias is mediated through nicotinic receptor desensitization. 
In sum, results from this study and others suggest that to achieve improvements in 
motor functioning in animals with motor disorders, nicotinic drugs must be administered for a 
prolonged duration, further supporting the hypothesis of nAChR inactivation as the underlying 
mechanism. However, further studies confirming nAChR inactivation under these experimental 
conditions are needed to confirm this interpretation. Furthermore, the specific brain regions and 
nicotinic receptor subtypes involved in this adaptation of gait following treatment with 
mecamylamine or varenicline remain to be elucidated, especially to confirm whether nicotinic 
receptor inactivation results in upregulation of nicotinic receptors that may ultimately underlie 
the behavioral recovery observed when these drugs are administered chronically. 
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4.7. Figures and Tables 
 
 
 
Fig. 4.1. Timeline of experimental paradigm. Rats were trained to walk on the DigiGait™ system 
for five consecutive days and assessed weekly thereafter for a total of four assessments. A PCA 
was performed using gait data from all animals at baseline (n=77) at 25 cm/s only, and the 
loading factors from this analysis were used to calculate CGI values across assessments. One 
week following the administration of 3-AP/nicotinamide, animals’ performance was reassessed 
to quantify gait impairments. One day later, animals were randomly assigned to one of six 
experimental conditions, receiving daily subcutaneous injections for a total of 13 days of either: 
saline + saline (n=15),  saline + 3 mg varenicline free base/kg/day (n=17), 0.8 mg 
mecamylamine free base/kg/day + saline (n=9), 0.8 mg mecamylamine free base/kg/day + 3 mg 
varenicline free base/kg/day (n=10), 3.2 mg mecamylamine free base/kg/day  + saline (n=8), or 
3.2 mg mecamylamine free base/kg/day + 3 mg varenicline free base/kg/day (n=9). 
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Fig. 4.2. Effects of 3-AP administration across time on CGI principal components. Z-scores 
were calculated for each animal’s gait parameter values and multiplied by the loading factors 
from the PCA to calculate the CGI. Overall CGI values and values for each principal factor were 
compared using a repeated-measures ANOVA and Fisher’s LSD post-hoc. Data represent 
mean ± S.E.M. of values from eligible saline-injected lesioned animals (n =12) and the asterisks 
denote significant differences from baseline determinations for each respective component. 
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Table 4.1. Principal component analysis at baseline. A principal component analysis was 
performed on gait parameter values obtained at baseline from all animals (n=77) at 25 cm/s 
only. For each parameter, the largest absolute loading value across the Factors is bolded, 
representing the primary components comprising each factor. 
Gait Measure Rhythmicity Thrust Contact 
Stride duration 0.972 0.225 -0.018 
Stride frequency -0.967 -0.192 0.045 
Stance duration 0.880 0.401 -0.119 
Propulsion duration 0.937 -0.022 0.092 
Braking duration -0.354 0.666 -0.353 
Swing duration 0.821 -0.219 0.198 
Stride length 0.973 0.223 -0.015 
Stance width -0.298 0.499 0.635 
Step angle -0.371 0.510 0.542 
Paw angle -0.276 0.628 -0.228 
Paw area 0.183 -0.145 0.728 
% Total variance 51.0 15.6 13.3 
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5.1. Translational and comprehensive approach to assess gait impairments in animals 
with olivocerebellar lesions 
 In a prior study, our laboratory utilized a static gait analysis and demonstrated that rats 
with olivocerebellar lesions exhibit deficits in stride length and stance width (Wecker et al., 
2013). While this method of gait assessment provides important insights into gait adaptations 
exhibited by animals with ataxia, it is limited, both in the number of gait parameters that can be 
investigated, as well as its inability to measure temporal aspects of gait. 
 Due to these limitations, we have undertaken a comprehensive approach to characterize 
gait deficits in animals with olivocerebellar lesions through the use of a motorized treadmill 
system (i.e. the DigiGait™). While this treadmill system has been used to assess gait deficits in 
other rodent models of motor disorders including spinal cord injury (Springer et al., 2010; Ek et 
al., 2010) and Parkinson’s disease (Glajch et al., 2012; Paumier et al., 2013), or in transient 
models of ataxia in mice (Hansen and Pulst, 2013), these studies represented the first use of 
this system in rats with persistent olivocerebellar ataxia as a result of 3-AP administration. This 
system confers numerous advantages over a static gait analysis, in that all animals can be 
forced to walk at a desired speed, obviating the confounding influence of speed on gait 
parameters (Cendelin et al., 2010). Moreover, this system can extensively capture more gait 
parameters than the static gait analysis method, allowing the collection of both temporal and 
spatial aspects of animals’ gait at baseline as well as following impairment to characterize gait 
deficits manifest as a result of ataxia.  
The results of this study illustrated that animals with olivocerebellar lesions exhibit 
alterations in their gait as a result of their impairment that persisted for several weeks. 
Importantly, results were obtained from two walking speeds, one which is a comfortable walking 
speed for rats (25 cm/s) (Gillis and Biewener, 2001; Laughlin and Armstrong, 1982), and a 
faster speed (35 cm/s) that is more challenging. This approach was especially important, given 
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that patients with ataxia exhibit more rhythmic gait with minimal variability at ‘preferred’ walking 
speeds, but at speeds outside of this range, gait variability and gait performance worsen 
(Schniepp et al., 2012; Wuehr et al., 2013). Thus, the use of two treadmill speeds allowed for a 
more comprehensive assessment of gait and expanded the comprehensive nature of this 
method of gait analysis. Furthermore, the use of a PCA to compact data from eleven 
temporospatial gait parameters revealed three primary factors that comprised gait and 
explained the majority of the variance in the dataset, including Rhythmicity, Thrust, and Contact 
(Lambert et al., 2014). These three factors were combined to yield a cumulative gait index (CGI) 
which illustrated that animals with olivocerebellar lesions exhibited a nearly 3-fold increase in 
gait deviation from ‘normal’. 
Importantly, the results of gait analysis of animals with olivocerebellar ataxia match 
findings from clinical studies of patients with ataxia, in that both species exhibit shorter stride 
lengths (Palliyath et al., 1998; Mari et al., 2012; Morton and Bastian, 2003), larger stance widths 
(or base of support) (Stolze et al., 2002; Mari et al., 2012; Ilg et al., 2007; Hudson and Krebs, 
2000; Serrao et al., 2013), increased foot/paw angle splay (Stolze et al., 2002), and increased 
variability in spatial measures (Palliyath et al., 1998; Stolze et al., 2002). In animals with 
olivocerebellar lesions, the magnitude of impairment was similar at both treadmill speeds.  
 Thus, these findings demonstrate the translational validity of this method of gait 
assessment, as well as its potential usefulness to test the effectiveness of therapeutics to 
improve gait deficits preclinically before they are tested in patients with ataxia. This conclusion 
is especially relevant given that gait analysis can be performed in both clinical and preclinical 
subjects and represents a translatable and objective method of assessing motor function and 
coordination. Thus, results of this study provided a foundation for future experiments to test the 
effectiveness of nicotinic drugs to improve gait dysfunction in animals with ataxia. 
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5.2. Varenicline at a higher dose is effective in improving gait impairments 
 With a comprehensive understanding of the gait adaptations manifest by rats with 
olivocerebellar ataxia and methodological tools to assess deviations from normal gait in these 
animals, it was next investigated whether the nicotinic agonist varenicline could attenuate gait 
impairments. The rationale for this approach originated from clinical studies documenting 
improvements in the gait and coordination of patients with varying subtypes of ataxia, including: 
fragile X tremor/ataxia syndrome (Zesiewicz et al., 2009a), spinocerebellar ataxia types 3 & 14 
(Zesiewicz and Sullivan, 2008), atypical Friedrich’s ataxia (Zesiewicz et al., 2009b), and 
spinocerebellar ataxia type 3 (Zesiewicz et al, 2012). As our prior study validated that the 
motorized treadmill system could detect gait adaptations as a result of ataxia in rats that 
matched those in humans with ataxia, it was investigated whether similar beneficial effects of 
varenicline could be obtained in animals with olivocerebellar lesions. Additionally, non-lesioned 
animals were employed to investigate the effects of repeated treadmill exposure on gait over the 
course of four weeks. 
 Results of this study demonstrated that normal, non-lesioned animals exhibit gait 
adaptations from normal as a consequence of repeated treadmill exposure, underscoring the 
commonsense, yet important finding that gait is dynamic and adaptable. These animals 
exhibited up to a 74% increase in gait deviation from normal merely two weeks following 
baseline assessment (Lambert et al., 2015). These gait adaptations included a longer total 
stride duration, longer stride lengths, and smaller stance widths, illustrating that animals became 
more efficient at walking on the treadmill following repeated exposure. 
For lesioned animals, results demonstrated that the daily administration of a high dose of 
varenicline for two weeks could attenuate both temporal and spatial gait impairments that 
rectified the timing of the gait cycle. Importantly, varenicline did not improve all gait impairments, 
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as deficits in several spatial parameters (i.e. paw angle, paw area, stance width) were still 
apparent following two weeks of varenicline administration. Rather, animals injected with the 
highest dose of varenicline adapted temporal aspects of their gait that rectified the timing of the 
gait cycle. Importantly, these attenuations of gait impairments were only present when animals 
were given the highest dose of varenicline tested (3 mg free base/kg), suggesting that a high 
dose is necessary to elicit improvements in motor function. 
 Importantly, results from these studies demonstrate that the effects of varenicline to 
attenuate gait impairments were speed-dependent, in that significant attenuations of gait 
impairments were only detected at the slower treadmill speed and not at the faster one. This 
could be due to increased gait variability at the faster speed, an interpretation that is supported 
by clinical findings that ataxic patients’ gait variability is speed-dependent, in that their variability 
is minimal at their preferred walking speed and increased at slower or faster speeds (Wuehr et 
al., 2013); (Schniepp et al., 2012). Thus, perhaps the increased variability at speeds faster than 
rats’ ‘comfortable’ walking speed (i.e. 25 cm/s) may have made it more difficult for animals to 
adapt measures of their gait in response to impairments. 
Also notable is that lesioned saline-injected animals exhibited recovery from the 
impairment in several gait parameters that was equivalent to values obtained at baseline. These 
results suggest that repeated treadmill exposure following impairment can improve deficits in 
gait, a finding that has been documented in other models of motor disorders including spinal 
cord injury (Wang et al., 2015; Cristante et al., 2013), Parkinson’s disease (Dutra et al., 2012; 
Lau et al., 2011), and stroke (Ke et al., 2011; Matsuda et al., 2011). However, as discussed, 
when compared to age-matched non-lesioned animals, lesioned saline-injected animals did not 
recover from the impairment to the same degree as animals injected with the highest dose of 
varenicline.  
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In this study, a principal component analysis was also employed to characterize the 
components of impaired gait (iPCA), illustrating that the relationships among gait parameters 
are affected following the lesion as well as the gait parameters themselves. Results of this iPCA 
were used to generate a cumulative gait index that characterized impaired gait (iCGI). On this 
measure, lesioned animals injected with the highest dose of varenicline uniquely altered their 
gait from the ‘normal’ impaired state as a result of attenuations of their gait impairments that 
was not present in lesioned saline-injected animals or the two lower doses of varenicline.  
Thus, this study confirmed that varenicline (at a high dose) could attenuate gait 
impairments in animals with olivocerebellar lesions, matching the clinical findings of Zesiewicz 
et al., (2012). In the double-blind clinical trial of Zesiewicz et al., (2012), beneficial effects were 
observed when varenicline was given at a dose of 1 mg/b.d., and required up-titration from 0.5 
mg/day over several weeks. This was recommended due to unwanted side effects of 
varenicline, including nausea, vomiting, and other gastrointestinal disruptions (Leung et al., 
2011), likely due to varenicline’s activity at other nAChR subtypes such as the α3β4 subtype 
present in autonomic ganglia or the 5-HT3 receptor (Lummis et al., 2011). It is unclear how the 
dose of 3 mg free base/kg to rats used in these studies (s.c., once daily) translates to the 
therapeutic dose of 1 mg (p.o., twice daily) in humans (Zesiewicz et al., 2012), especially since 
varenicline has a much shorter half-life in rats of 4 hours compared to 20-24 hours in humans 
(Obach et al., 2006). However, varenicline exhibits similarities between the two species in that it 
exhibits high bioavailability once absorbed, has good brain penetration, and demonstrates 
equivalent binding affinities at the α4β2 nAChR (Faessel et al., 2010; Rollema et al., 2007).  
 
5.3. Mecamylamine can similarly attenuate gait impairments 
 As results demonstrated that a high dose of varenicline improved motor deficits in 
animals with olivocerebellar lesions, it was next investigated whether mecamylamine could 
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block the effects of varenicline to attenuate gait impairments, thus providing insight into the 
mechanism of action of varenicline. Results demonstrated that chronic mecamylamine 
administration was equally effective as varenicline to attenuate gait impairments, and a similar, 
but not synergistic, effect was observed when high doses of the two drugs were used in 
combination, suggesting that mecamylamine and varenicline attenuate gait impairments through 
a similar mechanism.  
Since varenicline activates nicotinic receptors while mecamylamine blocks them, it 
seems paradoxical that both of these drugs resulted in attenuations of gait impairments. 
However, these drugs have a similar mechanism that may explain this finding. For example, 
chronic exposure to both nicotine and varenicline results in increased cell surface expression of 
nicotinic receptors, termed upregulation (Perry et al., 1999; Marks et al., 1992; Marks et al., 
2015, Hussmann et al., 2012). Similarly, chronic exposure to nAChR antagonists such as 
mecamylamine and the α4β2 competitive nAChR antagonist dihydro-β-erythroidine (DHβE) can 
upregulate nAChRs (Collins et al. 1994; Pauly et al. 1996; Abdulla et al., 1996; Zambrano et al., 
2015). Thus, it is likely that the mechanism of nAChR upregulation following prolonged 
exposure to nicotinic drugs is more complex than simple nicotinic receptor activation (i.e. an 
“outside-in” mechanism) (Kishi and Steinbach, 2006; Henderson and Lester, 2015). 
Rather, evidence suggests that the mechanism of nicotinic receptor upregulation is 
mediated primarily through intracellular mechanisms (i.e. an “inside-out” mechanism). For 
example, chronic exposure to nicotine increases the number and rate of assembly of immature 
nicotinic receptors within the endoplasmic reticulum (ER) (Henderson et al., 2014; Sallette et al., 
2005) as well as the insertion of mature receptors within the plasma membrane (Henderson et 
al., 2014). Immature intracellular α4β2 nAChRs pooled within ER can exist as two stochiometries 
that exhibit high-sensitivity (α4)2(β2)3 and low-sensitivity (α4)3(β2)2 for nicotine. Nicotine can 
readily penetrate the plasma membrane and act as a “maturation enhancer” (Sallette et al., 
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2005), promoting increased expression of this high sensitivity conformation (Nelson et al., 2003) 
within the ER at the expense of the low-sensitivity conformation. This interpretation is 
strengthened by the finding that nAChR upregulation does not require de novo protein synthesis 
(Wang et al., 1998); rather, the existing pool of nicotinic subunits residing within the ER can be 
recruited and trafficked to the plasma membrane for insertion.  
Therefore, following chronic exposure to nicotinic drugs over time, increased cell surface 
expression of this high-sensitivity conformation can result in increased nicotinic receptor 
sensitivity as well as increased receptor desensitization in response to the binding of agonists 
(Henderson and Lester, 2015). Indeed, nicotinic receptors have at least a 20-fold higher affinity 
for ligands when they are desensitized than when they are in the resting state (Quik and Lester, 
2002). Thus, while an “outside-in” mechanism of nicotinic receptor activation or desensitization 
following chronic exposure to nicotinic agonists alone is not sufficient to explain the 
phenomenon of nicotinic receptor upregulation, this “inside-out” approach provides a 
mechanism by which other findings suggesting that the effects of nicotinic drugs are mediated 
through desensitization can be interpreted (Henderson and Lester, 2015). For example, chronic 
administration of mecamylamine can attenuate L-DOPA-induced dyskinesias in a similar 
manner as nicotine, likely mediated through receptor desensitization (Bordia et al., 2008; 2010). 
Since by definition, desensitization occurs in response to prolonged exposure to an agonist, but 
not an antagonist (Ochoa et al., 1989), the interpretation of desensitization underlying the 
improvements in L-DOPA-dyskinesias can be explained through this “inside-out” mechanism. 
Therefore, it is plausible that the effects of both varenicline and mecamylamine to attenuate gait 
impairments as documented in this study are ultimately mediated through increased expression 
of nicotinic receptors. 
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5.4. Implications and Limitations 
 These experiments provide strong evidence that the nicotinic agonist varenicline and the 
nicotinic antagonist mecamylamine can improve gait impairments manifest as a result of 
olivocerebellar lesions in rats, and suggest nicotinic receptor inactivation as the underlying 
mechanism. Furthermore, these results lay the foundation for future experiments to be 
conducted using selective nicotinic agonists and antagonists to determine the identity of the 
nicotinic receptors facilitating this behavioral recovery. It is also worthwhile to investigate the 
specific brain regions involved in the motor improvement, be it within the cerebellum or its 
connections to other brain regions involved in the control of coordinated movement and gait. 
Additionally, these results demonstrate a method by which a cumulative gait index can be 
derived from the use of a principal component analysis to conceptualize the overall net effect of 
alterations in specific gait parameters upon gait as a whole and to investigate deviations from 
both normal and impaired states. 
A strength of these studies employing 3-AP administration to induce motor deficits in rats 
is that these animals can vary markedly in the degree of their impairment (Wecker et al., 2013; 
Lambert et al., 2014), and thus, this population of animals more closely resembles the 
heterogeneous human ataxia population. Results demonstrated that regardless of the degree of 
their impairment, nearly all animals (90%) given the highest dose of varenicline exhibited 
significant deviations from “normal” impaired gait on the iCGI that led to attenuations of gait 
impairments (Lambert et al., 2014). Thus, this finding further demonstrates the importance of 
employing a population of animals with varying degrees of impairment for studies that may yield 
relevant and translational findings.  
Furthermore, these studies demonstrate the usefulness and translational importance of 
employing a PCA to conceptualize the net effects of alterations in gait parameters. For example, 
while olivocerebellar lesions resulted in small, yet significant 10-20% changes in most gait 
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parameters, the use of a PCA to derive a CGI revealed that animals with ataxia exhibit a nearly 
3-fold increase in gait deviation as a consequence of their impairment (Lambert et al., 2014). 
The calculation of a PCA represents an objective method to weight the contribution of each gait 
parameter upon the gait cycle while maintaining the variability within the experimental 
population and reducing redundancy within the dataset.  
The first use of a PCA to produce a gait index that gained widespread clinical 
acceptance was generated by Schutte et al., (2000) and yielded a ‘normalcy index’ that was 
used to investigate gait alterations in patients with cerebral palsy. This method of using a PCA 
to conceptualize gait alterations has been shown to be effective in comparing a heterogeneous 
group of patients to one another, to test the progression of motor deterioration over time, and to 
investigate the efficacy of clinical interventions upon gait impairments (Cimolin and Galli, 2014). 
Additionally, a ‘gait deviation index’ has been employed to investigate deviations from ‘normal’ 
gait (Schwartz and Rozumalski, 2008), and has been used to quantify impairments in patients 
with Parkinson’s disease (Galli et al., 2012), muscular dystrophy (Thomas et al, 2010), and 
rheumatoid arthritis (Esbjörnsson et al., 2014). The results presented herein represent the first 
use of a PCA to calculate a cumulative gait index (CGI) to quantify deviations from normal gait 
in animals with ataxia. Thus, although comparisons between this specific index in animals and 
humans with ataxia are lacking, numerous reports documenting that ataxic patients exhibit 
increased gait variability compared to control subjects (Palliyath et al., 1998; Ebersbach et al., 
1999; Stolze et al., 2002) suggest that similar findings would be obtained if this index was 
employed in studies investigating the gait of patients with ataxia. 
5.4.1. Methodological limitations: animals and assessment paradigm 
Because male Sprague-Dawley rats were used in these experiments, it is unknown if 
similar effects can be obtained from female animals. Additionally, since these experiments 
required rats to undergo forced locomotion on a treadmill, sufficient data for gait analysis could 
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not be obtained from 20-30% of animals due to animal noncompliance. Thus, while it is 
unknown whether similar beneficial effects of varenicline can be obtained from other strains of 
rats or mice, it may be of benefit to employ other rodent models of ataxia for future experiments. 
Perhaps mice or other strains of rats are more compliant when subjected to forced locomotion, 
and thus, this may reduce the number of animals necessary for successful completion of the 
study. However, careful selection of the strain to be tested is warranted, since a study 
investigating treadmill performance among several strains of mice found considerable variability 
in animals’ compliance and gait parameter data depending upon the age, strain, and genetic 
background of animals used (Wooley et al., 2009). Thus, prior to conducting studies assessing 
gait on a treadmill, it is crucial to determine whether a large portion of the animal population to 
be used will be compliant during forced locomotion so that adequate gait measures can be 
obtained. For comparison purposes, it is also important to employ age-matched normal or wild-
type animals to investigate how gait parameters change over time as a consequence of 
repeated treadmill exposure. 
As discussed, animals were assessed at two treadmill speeds: 25 and 35 cm/s. 
Therefore, the effects of olivocerebellar lesions and treatment with nicotinic agonists and 
antagonists at speeds outside of this range cannot be determined from these results. A slower 
treadmill speed of 15 cm/s was employed during preliminary studies, but as this speed was not 
sufficiently challenging, most animals exhibited noncompliant behaviors such as turning or 
rearing that made data collection and subsequent analysis difficult. Thus, another 
recommendation for future studies is to employ treadmill speeds that are sufficiently challenging 
for animals so as to maximize compliance, but not fast enough that animals are overwhelmed 
by the rapidity of the treadmill belt and exhibit learned helplessness. Again, this caveat is 
especially important to consider when employing animals with progressive degenerative motor 
deficits, as their performance may worsen over time. 
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Furthermore, these experiments only provide information for gait parameters obtained 
from the hindlimbs of rats and not the forelimbs. This was for several reasons, including:  
animals reliably exhibited deficits in hindlimb parameters, whereas data from the forelimbs was 
less consistent, and whereas the hindlimbs in rats are used primarily for locomotion, the 
forelimbs have a dual functionality in locomotion as well as in foraging and environment 
exploration (Clarke, 1995). Thus, the use of a different species of animals (such as mice) where 
all four paws serve similar functions for locomotion may yield important insights into forelimb 
alterations in animals with gait, including whether the forelimbs compensate for hindlimb gait 
impairments or are similarly affected. Additionally, improvements in the temporal and spatial 
resolution of the DigiGait™ analysis software may streamline the process of gait analysis with 
fewer errors that need to be corrected by the experimenter post-hoc. 
Furthermore, the results of these studies are limited to the available gait parameter 
output provided by the proprietary DigiGait™ software, and mainly focus on the kinematics of 
animals’ movements (e.g. velocity, time). Other relevant gait information including the kinetics of 
animals’ movement (e.g. muscle function (EMG) or force displacement) cannot be quantified by 
this system. This is important given that patients with ataxia exhibit increased amplitude and 
duration of EMG bursts as well as greater force variability throughout the gait cycle in 
comparison to healthy controls (Martino et al., 2014). Thus, although results from these studies 
represent a comprehensive analysis of animals’ gait, the addition of other important aspects of 
gait such as the mechanisms that produce movement and the timing and actions of muscles 
involved may produce a more complete understanding when assessing gait abnormalities 
(Cimolin and Galli, 2014). 
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5.4.2. Pharmacological methodological limitations 
While a beneficial effect of varenicline was documented following chronic administration 
for two weeks, a longer time course of administration was not investigated. This was due to prior 
findings that both varenicline and nicotine exert a maximal effect to improve rotorod 
performance in animals with olivocerebellar lesions following two weeks of administration that is 
not improved by an additional two weeks (Wecker et al., 2013). Thus, it is possible that a longer 
time course of varenicline administration could result in greater improvements in motor function, 
such as improvements in spatial gait parameters that were not observed following two weeks of 
varenicline administration. Additionally, because the half-life of varenicline in rats is four hours 
(Rollema et al., 2007), it is possible that a greater improvement in motor function or attenuations 
of more gait impairments could be observed if varenicline was administered multiple times per 
day or chronically through osmotic minipumps. 
Although the highest dose of varenicline used in these studies (3 mg free base/kg) is 
among the highest doses given to rats reported in the literature, other studies have also used 
this dose to investigate the behavioral effects of varenicline (Spiller et al., 2009; O’Connor et al., 
2010). One study administered varenicline at a much higher dose of 10 mg free base/kg to rats 
and reported that this resulted in plasma levels of varenicline that are >50-fold higher than 
levels recommended for humans (Rollema et al., 2009). However, higher doses of varenicline 
can be given to rodent species, since they cannot vomit, a common unwanted side effect 
following the administration of high doses of varenicline in humans (Rollema et al., 2009; Leung 
et al., 2011). Due to these side effects, varenicline is only well-tolerated in humans at doses up 
to 2 mg/day (Faessel et al., 2006). 
While varenicline is FDA-approved for smoking cessation, its effects at 5-HT3 and 
autonomic α3β4 nAChRs may explain the emergence of reports of unwanted side effects 
including nausea, gastrointestinal disturbances, and suicidal ideations (Lummis et al., 2011). 
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These off-target effects may discourage its general use for the treatment of the symptoms of 
ataxia, especially since these effects are more likely to occur when varenicline is administered 
at a high dose (as recommended by the findings presented here). Fortunately, the field of 
nicotinic receptor research is continually discovering and testing novel nicotinic compounds that 
are more selective, including sazetidine-A (a potent α4β2 partial agonist) (Xiao et al., 2006) and 
ABT-089 (a α4β2 and α7 receptor partial agonist) (Rueter et al., 2004). Once the neuronal 
nicotinic receptor subtypes facilitating the effect of varenicline are elucidated, these more 
selective nicotinic compounds may provide equivalent or improved benefits in motor function 
with fewer side effects, and thus may be more beneficial for the heterogeneous group of 
patients with ataxia. 
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Appendix A: Additional Figures 
Fig. 2.4. Stability of gait measures and effects of treadmill speed. Both [A] temporal and [B] 
spatial gait parameters were determined from a representative stride sequence exhibited by 
control (unlesioned) animals at treadmill speeds of both 25 and 35 cm/s at 2 days following 
training and 9 days later. Bars represent mean values + s.e.m. of determinations from 11 
animals. Data were analyzed using a 2 × 2 (speed × assessment timepoint) repeated measures 
ANOVA with t-tests post hoc to assess differences. The asterisks indicate significant (p < 0.05) 
differences between speeds for: stride frequency, initial [t (20) = 5.97] and final [t (20) = 5.97]; 
stride duration, initial [t (20) = 6.02] and final [t (20) = 5.84]; stance duration, initial [t (20) = 8.28] 
and final [t (20) = 6.99]; braking duration, initial [t (20) = 2.23] and final [t (20) = 3.06]; propulsion 
duration, initial [t (20) = 5.34] and final [t (20) = 5.20]; stride length, initial [t (20) = 5.58] and final 
[t (20) = 4.29]; and step angle, final [t (20) = 2.56]. The double asterisks indicate significant (p < 
0.05) differences between assessments for stride frequency [t (10) = 2.25] and braking duration 
[t (10) = 2.52]. 
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Fig. 2.5. Effects of 3-AP on gait parameters. Both [A] temporal and [B] spatial gait parameters 
were determined from a representative stride sequence exhibited by animals 2 days prior to 
(initial) and 7 days following (final) the induction of an olivocerebellar lesion by the 
administration of 3-AP; parameters were determined at treadmill speeds of both 25 and 35 
cm/s. Bars represent mean values + s.e.m. of determinations from 45 animals. Data were 
analyzed using a 2 × 2 (speed × assessment timepoint) repeated measures ANOVA with t-tests 
post hoc to assess differences. The asterisks indicate significant (p < 0.05) differences between 
initial (pre-lesion) and final (post-lesion) assessments for: stride frequency, 25 cm/s [t (44) = 
3.77] and 35 cm/s [t (44) = 5.73]; stride duration, 25 cm/s [t (44) = 3.53] and 35 cm/s [t (44) = 
6.82]; stance duration, 25 cm/s [t (44) = 4.37] and 35 cm/s [t (44) = 7.68]; braking duration, 25 
cm/s [t (44) = 3.86] and 35 cm/s [t (44) = 5.32]; propulsion duration, 25 cm/s [t (44) = 5.37] and 
35 cm/s [t (44) = 11.0]; stride length, 25 cm/s [t (44) = 3.47] and 35 cm/s [t (44) = 6.80]; stance 
width, 25 cm/s [t (44) = 8.87] and 35 cm/s [t (44) = 7.08]; step angle, 25 cm/s [t (44) = 4.18] and 
35 cm/s [t (44) = 3.71]; paw angle, 25 cm/s [t (44) = 11.7] and 35 cm/s [t (44) = 11.3]; and paw 
area, 25 cm/s [t (44) = 9.83] and 35 cm/s [t (44) = 10.7]. 
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Fig. 4.3. Effects of saline or drug administration on absolute gait measures at the 3 week 
assessment. [A] Temporal and [B] spatial gait parameters at the final assessment timepoint 
were compared using a 2x3 MANOVA with Fisher’s LSD post-hoc. Data are presented as 
means ± S.E.M. from animals injected  with “Sal”: saline + saline (n=12),  Var: saline + 3 mg 
varenicline free base/kg/day (n=15), 0.8MEC: 0.8 mg mecamylamine free base/kg/day + saline 
(n=8), 3.2MEC: 3.2 mg mecamylamine free base/kg/day  + saline (n=7), 0.8MEC+VAR: 0.8 mg 
mecamylamine free base/kg/day + 3 mg varenicline free base/kg/day (n=7), or 3.2MEC+VAR: 
3.2 mg mecamylamine free base/kg/day + 3 mg varenicline free base/kg/day (n=9). 
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